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ABSTRACT
Reversible acetylation regulated by histone acetyltransferases (HATs) and
histone deacetylases (HDACs) plays a major role in transcriptional regulation.
HATs promote transcriptional activation by adding acetyl groups to the histone
tails, while HDACs act in the reverse process leading to transcriptional
repression. In addition to histones, HATs and HDACs also modify numerous
proteins, and therefore affect many biological processes. The HDAC family
consists of 18 members, which are grouped into four classes, namely I, II, III and
IV, with class II further subdivided into subclass IIa and IIb. HDAC6 is a
predominantly localized cytoplasmic deacetylase, which belongs to class IIb.
HDAC6 is unique among the HDAC family members in that it expresses two
complete functional deacetylase domains, a cytoplasmic anchoring motif, and an
ubiquitin binding domain. Like many other HDACs, HDAC6 has a growing list of
substrates. HDAC6 is known for its deacetylase activity towards cytoplasmic
proteins α-tubulin and cortactin, a function that is known to promote HDAC6mediated cell migration. HDAC6 is also regulated by post translational
modifications such as, phosphorylation, acetylation and ubiquitination. Using
mass spectrometric analysis, we have identified additional phosphorylation sites,
Threonine-1031 and Serine-1035, within the C-terminal of HDAC6. Both sites are
located within an extracellular signal regulated kinase (ERK) recognition motif,
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while Serine-1035 is a major site targeted by ERK. Previous studies have
identified ERK as a pivotal player in promoting tumorgenesis. HDAC6 was
identified as a major player in promoting cell migration, and was also shown to be
required for efficient oncogenic tumorigenesis. However, whether ERK can
regulate HDAC6 to promote cell migration have not been investigated. Based on
published data and our preliminary results, we hypothesized that 1) Serine-1035
of HDAC6 is a major phosphorylation site of HDAC6 that plays a critical role in
promoting HDAC6-mediated cell migration by affecting deacetylation of its
substrates; and 2) HDAC6 promotes cell migration in vivo. Using in vitro and in
vivo studies, we confirmed that Serine-1035 of HDAC6 is phosphorylated by
ERK1. In addition, we found that activation of the ERK-mitogen activated protein
kinase (MAPK) signaling axis promotes HDAC6 phosphorylation. By using
unphosphorylation mimicking mutants of HDAC6 Serine-1035 site, we observed
that unphosphorylation of HDAC6 at this site does not affect HDAC6 enzymatic
activity towards histones or cortactin. However, unphosphorylation of HDAC6 at
Serine-1035 hinders HDAC6’s ability to deacetylate α-tubulin and β-catenin.
Importantly, hypo-phosphorylation of HDAC6 at this site significantly attenuates
its ability to promote cell migration using the cell lines model. We showed for the
first time that HDAC6 also promotes metastasis in vivo using a mouse model. In
conclusion, this study identified HDAC6 Serine-1035 as a novel phosphorylation
site which can be phosphorylated by ERK1, and this phosphorylation status of
HDAC6 can promote cell migration. Since the ERK-MAPK pathway is a major

vii

target of numerous signaling events, inhibitors of both ERK and HDAC6 may
prove beneficial for future research directions.
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CHAPTER ONE
INTRODUCTION
An Overview of Histones
The core histone molecule is evolutionarily conserved and is formed by
histones H2A, H2B, H3 and H4 (1). The nucleosome is the repeating unit of
chromatin. These units are formed by approximately 145-147 base pairs of DNA
wrapped around a histone octamer, that consists of an H3-H4 tetramer and two
H2A-H2B dimers (1). The N-terminal tails of the histones are very flexible, and
therefore, are involved in neighboring nucleosome interaction and nuclear factor
interactions (1). The N-terminal tail of the histones can also be covalently
modified through reversible post-translational modifications such as lysine
acetylation, lysine and arginine methylation, serine and threonine
phosphorylation, ADP-ribosylation, ubiquitination, and sumoylation (2). Histone
acetylation is one of the most understood modifications, that occurs on the εamino group of evolutionarily conserved lysine residues (3). Histone
acetyltransferases (HATs) and histone deacetylases (HDACs) act in a reversible
manner to either add or remove an acetyl group on the histone tail, respectively
(4). These modifications affect chromatin conformation and lead to either
transcriptional activation (hyperacetylated histones) in the case of HATs or
transcriptional repression (hypoacetylated histones) in the case of HDACs (4, 5).
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An Overview of Histone Deacetylases
Eighteen HDACs are grouped into four classes (I, II, III and IV) according
to their size and structure (6). Class I HDACs are ubiquitously expressed and
consist of HDACs 1,2,3 and 8. Class I HDACs are closely related to the yeast
(saccharomyces cerevisiae) transcriptional regulator, reduced potassium
deficiency 3 (RPD3) (3). Two class I HDACs (1 and 2) were identified as
components of multiprotein complexes such as Sin3/HDAC and NuRD/Mi2/NRD
(7). Class II HDACs are divided into two subclasses, class IIa and class IIb.
Class IIa consists of HDACs 4, 5, 7, and 9, whereas class IIb consists of HDAC6
and 10. Class II HDACs show a tissue specific pattern of expression. They also
share similar domains with another deacetylase found in yeast, HDA1 (3, 5).
Class III HDACs consist of 7 sirtuins (silent information regulator 2 (sir2)-related
protein) SIRT 1-7 (8). Class IV only consists of one member, HDAC11. HDAC11
contains conserved residues within its catalytic core region that are shared by
both class I and class II HDACs (9).
HDACs are not known to bind directly to DNA, but they are recruited to
specific promotes because of their interaction with DNA sequence specific
transcription factors (5). HDACs consist of nuclear localization signals (NLS) that
allow HDACs to reside in the nucleus. However additional regulatory domains
may influence the cytoplasmic localization of many HDACs (10). Class I HDACs
are found mostly in the nucleus, in particular, HDAC1 and HDAC2, because of
the absence of a nuclear export signal (NES) (3). Class II HDACs display
shuttling activity between the nucleus and cytoplasm in response to cellular
2

signals (3). In addition, class II HDACs interact with the chaperone protein 14-33, that allows for nucleo-cytoplasmic shuttling (5). Binding of 14-3-3 to the
phosphorylated serine residues in the N-terminus of HDACs masks the nuclear
import signal thus preventing them from entering the nucleus (5). The class IV
HDAC, HDAC11, localizes to the nucleus but may also form a complex with
HDAC6 in the cytoplasm (11).
HDACs catalytic domains are formed by approximately 390 amino acids,
consisting of some conserved amino acids. Crystal structures revealed an HDAC
catalytic core consisting of a tubular pocket, a zinc binding site, and two
asparagines and two histidines that form hydrogen bonds. This arrangement
within the catalytic domain forms a charge relay system similar to the active sites
of serine proteases. The residues within the active site are conserved across the
HDAC family members (12). The Zn2+ ion is an essential component of the
charge relay system. The wall of the pockets consists of hydrophobic and
aromatic residues identical to that of HDAC1 (12). The class I, II and IV classic
families require Zn2+ for deacetylase activity and share similarity in their
sequences (8). On the other hand, class III HDACs do not display sequence
similarity to the classic family of HDACs and require NAD+ as a cofactor (8).

Acetylation of Non-Histone Proteins
Acetylation on lysine residues is a conserved post translational
modification (PTM) from prokaryotes to humans (13, 14). Apart from histones,
3

numerous other proteins are also modified by acetylation. Many of these
acetylated proteins are involved in processes including RNA splicing, cell cycle,
chromatin remodeling, protein phosphorylation, DNA damage and repair,
cytoskeleton reorganization, and transcription (14, 15). HATs and HDACs are
also subject to acetylation (14, 15). Many acetylated proteins are important
factors in pathways that are implicated in cancer (13). In addition to cancer,
acetylation and deacetylation processes have been linked to other disease
states, such as neurodegeneration, cardiovascular disorder, inflammation, lung
disease, and aging (16). In some cases non-histone proteins are deacetylated by
more than one HDACs, as in the case for p53. The tumor suppressor p53 was
the first identified non-histone HDAC substrate, and it can be deacetylated by
both HDAC1 and SIRT1 (13). The cytoplasmic protein α-tubulin is also another
such protein that can be deacetylated by both HDAC6 and SIRT2 (15).

Phosphorylation of Histone Deacetylases
PTM of any protein has the ability to modulate the protein’s functions, its
enzymatic activity, its subcellular localization, its stability, and its interactions with
other binding partners (17). HDACs are strongly regulated by phosphorylation as
well. HDAC1 is phosphorylated by casein kinase 2 (CK2) both in vitro and in vivo.
Studies have shown that disrupting HDAC1 phosphorylation by CK2 results in
diminished HDAC1 enzymatic activity and complex formation (18). Like HDAC1,
HDAC2 is also phosphorylated by CK2. This modification is critical for HDAC2
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complex formation with mSin3 and Mi2, and is also important for HDAC2
enzymatic activity but not necessary for transcriptional repression (19).
Phosphorylation of HDAC1 and HDAC2 disrupts HDAC1/2 complex formation, as
well as the interactions of HDAC1 between corepressors mSin3A and YY1 (20).
This may suggest that phosphorylation of HDAC1 and HDAC2 hinders
transcriptional repression (20). HDAC3, another class I HDAC, can also be
phosphorylated by CK2. This phosphorylation event is critical for HDAC3’s
enzymatic activity (21). Dephosphorylation also affects the activity of HDAC3.
The protein phosphatase PP4c dephosphorylates the same site (Serine 424)
phosphorylated by CK2 on HDAC3. The phosphatase activity leading to
dephosphorylation of HDAC3 resulted in reduced HDAC3 enzymatic activity (21).
HDAC8 can be phosphorylated by protein kinase A (PKA) both in vitro and in
vivo. Mutation of the phosphorylation site to mimic an unphosphorylated form
enhances HDAC8 deacetylase activity, whereas enhanced phosphorylation by
an activator, or by a phospho-mimetic, resulted in decreased enzymatic activity
of HDAC8 and enhanced acetylation of histones H3 and H4, indicating the
importance of PTM on histone acetylation status (22).
Class II HDACs are involved in nucleo-cytoplasmic shuttling, an event that
is dependent on phosphorylation. HDAC4 is present in both the cytoplasm and
the nucleus. HDAC4 was shown to be associated with extracellular signal
regulated kinase (ERK1/2), leading to HDAC4 phosphorylation and increased
localization in the nucleus (23). In addition to ERK1/2, HDAC4 can also be
phosphorylated by calcium/calmodulin-dependent protein kinase IV (CaMKIV),
5

which can also affect HDAC4 subcellular localization by promoting HDAC4’s
nuclear export (24). As such, phosphorylation of HDAC4 regulates its intracellular
localization (23)
PKA phosphorylates HDAC5 and was shown to prevent HDAC5’s nuclear
export, further resulting in suppressed gene transcription (25). This
phosphorylation event blocks the interaction between HDAC5 and the protein
chaperon 14-3-3 involved in nuclear export (25). The nuclear export of HDAC7 is
also mediated by 14-3-3. Both HDAC5 and HDAC7 subcellular localization can
be controlled by CaMK1 and 14-3-3 (26). In addition, it was shown that PKC
related kinase (PRK 1/2) interacts with HDAC5 mapped to its nuclear localization
signal (27). Altogether, these results indicate that more than one site within the
HDACs structure can be phosphorylated by different kinases.

Clinical Relevance of Histone Deacetylases
Acetylation and deacetylation of histones affect numerous gene
expression in processes implicated in cancer promotion, such as angiogenesis,
cell adhesion, cell migration, cell invasion, and cell proliferation (10). In vitro
model using HDAC inhibitors (HDACi) have also suggested that HDACs are
involved in tumor development. It is thought that the use of HDACi leads to
increase acetylation and increase recruitment of DNA binding transcription
factors (TFs), which alters gene expression (3, 10). The use of HDACi may prove
to be beneficial, because HDACi inhibits cell proliferation, promotes
6

differentiation and can also cause apoptotic induction (10). HDACs lead to
transcriptional repression by removing the acetyl group from the histone tails
resulting in a compact chromatin structure. This prevents the entry of TFs that
are usually necessary for transcriptional promotion (10). Specifically, HDACi
function by binding to the Zn2+ ions needed for HDACs catalytic functions (12).
HDACi, therefore, de-represses the inhibitory function of HDACs. This is
important because repressed genes are often tumor suppressors, such as cell
cycle inhibitors, differentiation factors or inducers of apoptosis (10).
HDACs are not just for histones, numerous non-histone proteins are being
identified as HDACs substrates including TFs, chaperons, signaling mediators
and DNA repair proteins only to name a few (28). Because HDACs are involved
in numerous cancer progression processes, the use of HDACis in preclinical
setting is becoming more apparent. In fact, HDACi are being investigated as a
clinically relevant treatment option for cancer (29). HDACis are separated into
four different groups that include the short chain fatty acids, hydroxamic acids,
cyclic tetrapeptides, and benzamides (28). The HDACi, vorinostat
(suberoylanilide hydroxamic acid (SAHA)), was the first one approved by the
U.S. Food and Drug Administration (FDA) in 2006 for treatment of cutaneous Tcell lymphoma (CTCL) in patients with progressive, persistent or recurrent
disease (30). Treatments have shown positive results in lymphoid neoplasm, but
have been less effective for solid malignancy. Side effects from this treatment
option showed fatigue, weakness, diarrhea, and vomiting and minimal toxicity
(30). SAHA is a pan-HDACi which can potently inhibit class I and class II HDACs,
7

resulting in effects such as cell cycle arrest in transform cells due to up-regulation
of the cyclin-dependent kinase inhibitor, p21WAF1 (31). Experiments using this
inhibitor showed increased acetylation of histone H3 and H4 in chromatin
associated with the cyclin dependent kinase inhibitor, p21WAF1 gene, with
subsequent increase in p21WAF1 expression in bladder transitional cell carcinoma
cells (32). Other HDACi, such as depsipeptide also showed down regulation of
cyclin D1 and upregulation of p21WAF1 leading to further G1 cell cycle arrest (33).
In addition, HDACi in combination with other drugs, such as DNA methyl
transferase inhibitors (DNMTi), is also being explored for the treatment of
hematological malignancies, as well as for solid tumors (29, 34). Because
HDACs not only affect the acetylation status of histones but also non-histone
proteins, their activity in disease states, such as cancer, is becoming more
widespread. Since HDACs are essential for many cellular functions, the above
pan-HDAC inhibitors are usually toxic to the patients. It is important to
understand the functions of individual HDAC, which may aid in the development
of novel HDAC-specific inhibitors for cancer treatment.

An Overview of Histone Deacetylase 6
The class IIb HDAC6 is mainly a cytoplasmic protein (35, 36). However, in
some instances, as in the case of arrest in cell proliferation, a fraction of mouse
HDAC6 (mHDAC6) can be found in the nucleus (36). Human HDAC6 (hHDAC6)
consists of one nuclear localization signal (NLS) and two nuclear export signals
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(NES), double deacetylase domains, eight consecutive serine-glutamic acid
containing tetradecapeptide (SE14) repeats, and a zinc-finger domain (Figure 1).
Like other HDACs, localization of HDAC6 is controlled by its localization signals.
hHDAC6 possesses two NES; one located in the N-terminus and the other in the
C-terminus, and an N-terminus NLS (35). On the other hand, mHDAC6
possesses three nuclear export signal-like motifs (36). HDAC6 is unique among
the HDACs, in that it contains two catalytically functional domains that are
arranged in tandem (3). This similarity is shared by the other class IIb HDAC
member, HDAC10.(37).
HDAC6 also possesses a zinc finger domain termed ubiquitin carboxylterminal hydrolase like zinc finger (ZnF-UBP) within its C-terminal region (38).
This feature of HDAC6 allows it to be associated with monoubiquitin and
polyubiquitin (38-40). HDAC6 itself can be ubiquitinated both in vitro and in vivo,
but HDAC6 is a relatively stable proteins in vivo (39). An SE14 repeat domain is
also present within the C-terminus of hHDAC6, but is excluded from murine,
C.elegans, and drosophila (35). Size exclusion chromatography using full length
HDAC6, deletion of the zinc finger domain or both deletion of the zinc finger
domain and SE14 motif, suggested that it is possible for the SE14 repeat domain
to form an unusual structure and this in turn affects the overall structure of
hHDAC6 (35). The cytoplasmic localization of hHDAC6 is also regulated through
a different mechanism than that of mHDAC6. The SE14 motif found on hHDAC6
may account for HDAC6 cytoplasmic retention (35). Furthermore, the multiple
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motifs to ensure HDAC6’s presence in the cytoplasm, may suggest that
evolutionary pressures reinforced HDAC6 localization in the cytoplasm (41).

Post Translational Modification of HDAC6
Acetylation of HDAC6
PTM of HDAC6 affects its functions, localization and interactions with its
substrates. It was previously shown that HDAC6 can be acetylated by the HAT,
p300. Acetylation of HDAC6 negatively regulates HDAC6 deacetylase activity
(42). Consistently, another study showed that acetylation of HDAC6 by p300
decreases HDAC6 ability to deacetylate its cytoplasmic substrate, α-tubulin,
which negatively affects its ability to promote cell motility (43). HDAC6
localization to the nucleus is dependent on its interaction with importin α, an
interaction that is hindered by acetylation. The localization of HDAC6 in the
nucleus promotes deacetylation of histones and other HDAC6 nuclear
substrates. However, when HDAC6 is acetylated, HDAC6 is retained in the
cytoplasm and deacetylation of histones are hindered (43).

Phosphorylation of HDAC6
Like many of the other HDACs, HDAC6 can also be phosphorylated by
different kinases. Glycogen synthase kinase 3β (GSK-3β) was shown to
phosphorylate HDAC6 at its Serine 22 site located in the N-terminus. The
10

consensus phosphorylation site recognized by GSK-3β is also shared by kinases
CdK5 and p38 MAPK (44). Inhibition of GSK-3β mediated phosphorylation of
HDAC6 results in a decreased deacetylase activity in cytoplasmic extracts of
hippocampal neurons, and increased α-tubulin acetylation (44). Aurora A is a
centrosomal kinase that is involved in regulating mitotic entry. Aurora A was also
shown to phosphorylate HDAC6, to promote its deacetylase activity towards its
substrate α-tubulin and subsequently to promote cilia disassembly. However,
Aurora A’s phosphorylation site is yet to be identified (45). HDAC6 C-terminal
catalytic domain at residue tyrosine 570 can be phosphoryated as well. However,
phosphorylation at this site negatively regulates HDAC6 catalytic activity,
resulting in increased α-tubulin acetylation which influences epidermal growth
factor receptor (EGFR) trafficking (46). Therefore, it appears that the location of
the phosphorylation sites, as well as the kinases involved, determines how
HDAC6 activity is regulated.

Cytoplasmic Substrates of HDAC6
As a predominantly cytoplasmic deacetylase HDAC6 is involved in
promoting many cellular functions including cell migration, lymphocytes
chemotaxis, immune synapse formation, degradation of mis-folded proteins, and
the clearance and regulation of glucocorticoid receptors (47). HDAC6 promotes
its function through many of its substrates and interacting proteins. However,
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some of the well known cytoplasmic substrates of HDAC6 are α-tubulin,
cortactin, and HSP90 (48-50)

α-Tubulin
Microtubules (MT) are cytoskeletal polymers made up of α and β tubulin
heterodimers found within all eukaryotic cells. They are involved in multiple
biological processes, such as mitosis, cell motility, intracellular transport,
secretion, cell shape maintenance, and cell polarization (51). Post translational
modifications, such as acetylation, can affect the microtubule network,
particularly, the α-subunit of tubulin (52). Lysine 40 of the α-subunit can be
modified because of its position on the luminal surface of microtubules (52).
HDAC6 was shown to be associated with the MT network and deacetylates αtubulin (48, 53). HDAC6 can deacetylate α-tubulin both in vitro and in vivo to
regulate microtubule stability (53, 54). HDAC6 also colocalizes with the MT
network, and inhibiting HDAC6 enzymatic activity using HDACi, as well as
targeted inactivation resulted in hyperacetylation of the MT (53). HDAC6 is
involved in regulating the stability of MTs, as overexpression of HDAC6 was
observed with polymerized MTs, whereas HDAC6 knockdown expression
increased MTs stability (55). There are conflicting data as to whether one or both
HDAC6 deacetylase domains are required for its activity towards α-tubulin.
Zhang et al., showed that both HDAC6 catalytic domains are required for
deacetylation of tubulin. Mutation in one deacetylase domain of HDAC6 was
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sufficient to eliminate its entire activity, this result suggests that the cooperation
between the two domains are necessary for activity (53). In addition to the two
required domains, the arrangement of the two domains is important as well.
Altering the linker region between the two domains affects HDAC6 deacetylase
activity towards histones and α-tubulin (56). Another group showed that HDAC6
deacetylase activity towards α-tubulin is contained only in its C-terminal catalytic
domain (57). The association of HDAC6 with the MT network and subsequent
deacetylation of α-tubulin were shown to promote cell migration (48, 57). HDAC6
is concentrated at high protrusive region, such as lamellipodium. HDAC6
deacetylation of tubulin is required for fibroblast invasive motility, as inhibition of
HDAC6 leads to increased in steady state levels of focal adhesion, as well as
decreased MT dynamics. A decrease in MT dynamics causes an increase focal
adhesion accumulation and a decreases motility in fibroblast (58). Tubulin
hyperacetylation is necessary and sufficient to increase cellular adhesion.
Hyperacetylation of MT due to HDAC6 deficiency results in larger adhesion and
greater total adhesion area due to affected focal adhesion turnover (58). In
migratory lymphocytes, however, HDAC6 deacetylase activity is not involved in
promoting cell migration. It was suggested that HDAC6 may have a scaffolding
role that are important in lymphocyte migration (59). In terms of trafficking within
the cells, HDAC6 deacetylation of MT affects endocytosis of EGFR, as well as its
degradation (46, 60). In cytstic renal epithelial cells, HDAC6 was shown to
regulate endocytic trafficking of EGFR, as well as its degradation. Inhibition of
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HDAC6 results in a more stable MT network that allows transport of EGFR
containing vesicles and further degradation (61).

Cortactin
HDAC6’s ability to promote cell motility is facilitated not only through the
microtubule network but also other factors associated with the actin cytoskeleton.
Cortactin is a multi-domain protein, that is involved in the regulation of actin
cytoskeleton and influences cytoskeleton reorganization through extracellular
and intracellular stimuli (62). Cortactin’s structure is made up of a series of six
complete and one incomplete repeating sequence arranged in tandem. The
repeat region of cortactin is involved in its binding activity to F-actin (62). In an
unstimulated environment, cortactin localizes to the cytoplasm, but upon
stimulation by growth factors, etc. cortactin relocalizes to the cortical actin
network. Cortactin is known to be associated with actin-based protusion
structures, lamellipodia formation, and adhesion (62). The initial step involved in
cell movement is lamellipodial protrusion. It was shown that lamellipodial
persistence is enhanced by cortactin through regulation of the Arp 2/3 complex.
Cells with cortactin knock down expression showed defects in the assembly of
new adhesions in protrusion, as well as defects in motility and invasion (63).
Post-translational modification of cortactin is also necessary for its role in cell
migration and angiogenesis. Indeed, both HDAC6 and another class III HDAC,
SIRT1, were shown to be involved in one or more of these processes (50, 64,
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65). Both HDAC6 deacetylase domains are required for the deacetylation of
cortactin, which alters the binding of cortactin to F-actin (50). Cortactin mutants
with the ability to neutralize the charged patches, which results in decreased
binding between cortactin and F-actin, were less motile. This result suggests a
role for HDAC6 in actin dependent motility through its ability to deacetylate
cortactin (50). HDAC6 deacetylation of cortactin is also necessary for processes,
such as angiogenesis, both in vitro and in vivo, as well as migration and
sprouting in endothelial cells (64).

Heat Shock Protein 90
The molecular chaperone HSP90, is another acetylated protein that is a
target of HDAC6 deacetylase activity. Inactivation of HDAC6 leads to
hyperacetylation of HSP90 causing its disassociation from its cochaperone, p23,
and hindering its chaperone function (49). In addition, inhibition of HDAC6 results
in a decreased binding of HSP90 to ATP, and further reduced chaperone
function of HSP90 with its client protein, Bcr-Abl. This leads to polyubiquitination
of Bcr-Abl and subsequent depletion of intracellular levels of Bcr-Abl, C-Raf, and
AKT (11). Cell motility and macropinocytosis are regulated through HDAC6 and
its substrate, HSP90. HDAC6 and HSP90 association in response to growth
factors such as platelet-derived growth factor (PDGF), leads to activation of Rac1
and efficient ruffle formation and cell migration (66).
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β-Catenin
β-catenin is another cytoplasmic substrate of HDAC6 that has recently
emerged (67). β-catenin is a cytoplasmic protein that plays a role in determining
cell fate through patterns and structure formation (68). β-catenin structurally
consists of an N terminal, a C terminal, and a middle region domain. The middle
region domain consists of twelve repeats of forty-two amino acids, that are
considered to be a single functional unit. Each repeat forms a α-helices and a
connecting loop (69-71). The sequences of β-catenin repeats vary significantly,
however, the size and hydrophobic core are highly conserved (69). In addition,
the repeats serve as the binding site for numerous of β-catenin binding partners
(70, 71).
β-catenin is a key effector involved in signal transduction through the
canonical wnt pathway (72). The wnt pathway is a conserved cascade that is
involved in the regulation of animal development from Cnidarians to mammals
(72). Wnt signaling is involved in regulating cell proliferation and differentiation
and is also involved in gene transcription and cell adhesion (73). Activation of the
wnt pathway through β-catenin leads to transcriptional activation of wnt-specific
genes that are important for controlling cell fate in many cells and tissues (72).

Regulation of β-catenin
Two different pools of β-catenin are usually found in the cell. The first
being the stable form that is involved in cellular adhesion. It is usually found at
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the membrane in association with E-cadherin and α-catenin. The second being
the highly unstable form within the cytoplasm that can be found associated with
axin and APC and is targeted for proteosomal degradation (68, 74). The stability
and function of β-catenin is controlled by PTM, such as acetylation and
phosphorylation. Phosphorylation of β-catenin at sites serine 33, 37, 45 and
threonine 41 are conserved from drosophila to human (75). Mutations at these
residues are frequently found in human colon cancer and other malignancies
(75). It has been determined that β-catenin is phosphorylated from the C-terminal
to the N terminal starting with serine-45, threonine-41, serine-37 then finally
serine-33. Knock down of the kinase CK1α diminished β-catenin serine-45
phosphorylation, as well as the other sites phosphorylation, indicating the
importance of CK1α in β-catenin control (75). Cytoplasmic β-catenin is regulated
by the destruction complex consisting of the tumor suppressor proteins axin, and
adenomatous polyposis coli (APC) and two serine-threonine kinases GSK3 α/β
and CK1 α (68, 76). In the absence of wnt signaling, β-catenin bound to axin is
phosphorylated first by CK1 then GSK3 (68). Phosphorylated β-catenin is
recognized by SCF-βTrCP which is a part of an E3 ligase complex. This leads to
ubiquitination of β-catenin and ultimately degradation by the proteasome (68). βcatenin is first phosphorylated by CK1α and this modification is necessary for
subsequent phosphorylation by GSK-3β, as mutation at serine33 or serine37
prevents phosphorylation dependent recognition by SCF-βTrCP, but mutation at
threonine41 or serine45 did not (75). Phosphorylation at these sites therefore
serves as a SCF-βTrCP recognition motif (74). On the other hand, with activation
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of the wnt/β-catenin pathway, β-catenin ubiquitination is inhibited, and the
accumulated β-catenin is translocated to the nucleus and activates its target
genes (68).
Like numerous other non-histone proteins, β-catenin was identified as an
acetylated protein (67, 77). Acetylation of β-catenin by the HAT, p300/CBPassociate factor (PCAF), improves β-catenin’s stability through the inhibition of
ubiquitin-dependent degradation. Acetylation of β-catenin also allows its
translocation to the nucleus to enhance its transcriptional activity (77). In addition
to other identified acetylation sites, lysine-49 in its amino (N) terminal region is a
conserved acetylation site from drosophila to human. It was determined that
acetylation at lysine-19 and lysine-49 prevents ubiquitation of β-catenin and
therefore its degradation (77). β-catenin was also shown to be acetylated by
CREB binding protein (CBP) at lysine-49, a site that is frequently mutated in
thyroid cancer (78). It was determined that unacetylated lysine-49 is a potent
activator of the c-Myc genes, and that mutation of β-catenin at lysine-49 does not
affect β-catenin stability or interaction with the wnt pathway members or βcatenin nuclear localization (78).
β-catenin was also shown to be acetylated by p300 at lysine-345 within
the 6 arm repeat region. Mutation of β-catenin at lysine-49 and lysine-345
showed a significant reduction in acetylation. Acetylated β-catenin at lysine-345
by p300 showed increased affinity of β-catenin for TCF4. This interaction
increases the co-activator function of β-catenin resulting in increased
transcriptional activity (79). HDAC6 association with β-catenin was shown to be
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in the presence of epidermal growth factor (EGF). EGF stimulation in cells results
in translocation of HDAC6 from the cytoplasm to the caveolae membrane, where
HDAC6 associates with and deacetylates β-catenin on lysine-49. Deacetylation
of β-catenin by HDAC6, results in β-catenin translocation to the nucleus, where it
activate target genes, such as c-Myc (67).

Clinical Relevance of HDAC6
Through deacetylation of its cytoplasmic substrates, HDAC6 was shown to
promote processes that are involved in oncogenesis, such as cell motility and
angiogenesis (48, 50, 64). HDAC6 is required for oncogenic transformation
induced by Ras in primary cell lines. It is also required for the maintenance of
anchorage independent growth in established cancer cell lines. HDAC6
deacetylase activity is required for malignant growth in cancer cells in vitro, since
studies have shown that loss of HDAC6 leads to reduced tumor growth (80).
HDAC6 protein expression is up-regulated in ovarian cancer cell lines and
tissues. In addition, HDAC6 was shown to promote ovarian cancer cell motility
and migration (81). In non-migratory cells, HDAC6 is usually localized to
punctuate structures around the nuclei, however, in migratory ovarian cancer
cells, HDAC6 is localized to the leading edge of cells (81). Because of the role
HDAC6 plays in the cancer disease processes, understanding the mechanism
through which HDAC6 promotes these processes would be beneficial.
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An Overview of the Mitogen Activated Protein Kinase Family
Protein phosphorylation is a well-known post-translational modification
that is involved in signal transduction (82). The process of phosphorylation or
dephosphorylation is a reversible reaction that uses kinases to promote
phosphorylation and phosphatases in the reverse process (82).
The mitogen-activated protein kinase (MAPK) pathway represents an
evolutionary conserved phospho-relay system that includes the extracellular
signal regulated kinase (ERK 1/2) family, the p38 kinase family, c-Jun-N terminal
kinase (JNK) family and ERK5. MAPK can be activated by many cellular signals
that are then converted into a wide range of cellular responses (82, 83). While
the ERK-MAPK pathway is activated by growth factor stimulated surface
receptors, the other MAPKs, namely, p38, JNK and ERK5 are activated by stress
and growth factors (84). Each of the MAPK signaling axis consists of MAPK
kinase kinase (MAPKKK) that activates MAPK kinase (MAPKK), which then
leads to the activation of MAPK through phosphorylation of threonine and
tyrosine residues within the MAPK activation loop (82). Once the MAPKs are
phosphorylated, they then phosphorylate serine or threonine residue on their
downstream target substrates, which are localized to many subcellular locations
within the cells including the cytoplasm, mitochondria, Golgi, endoplasmic
reticulum and nucleus (82, 83, 85). The specificity of the MAPK response
depends on activation of different module and scaffolding protein with respect to
different stimulus (86). For instance, scaffolding proteins, such as kinase
suppressor of ras-1 (KSR) and MEK partner 1 (MP1), are found within the ERK20

MAPK module and mediates ERK pathway activation (87). MAPK regulates
numerous cellular processes including cell proliferation, cell adhesion, cell cycle
progression, cell migration, cell survival, differentiation, transcription, metabolism,
inflammation, stress response, and oncogenesis (82, 83, 85).

The ERK–MAPK Pathway
The first elucidated MAPK pathway was that of ERK1/2 MAPK (85). This
pathway like many other pathways is not a simple linear model, but rather a
complicated network that can be influenced by other pathways, and scaffolding
proteins. However, a simplified module of the ERK-MAPK pathway consists of
sequential phosphorylation and activation of Ras -> Raf -> MEK1/2 -> ERK1/2.
ERK1 and ERK2 are the last kinases within the pathway, phosphorylating
approximately two hundred substrates (82, 85).
Within the ERK-MAPK pathway, growth factors bind to their receptor
tyrosine kinases, leading to receptor dimerization and auto phosphorylation of the
receptor tyrosine residue. The phosphorylated tyrosine serves as a docking site
for adaptor proteins known as growth factor receptor binding protein (Grb2) and
the exchange factor, son of sevenless (SOS). The assembly of the signaling
complex leads to Ras activation through which Ras bound guanosine
diphosphate (GDP) is exchanged for guanosine triphosphate (GTP). This
exchange causes a conformational change in Ras which allows its binding to Raf
(88). The Ras family of genes consists of three functional genes, namely H-ras,
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K-ras and N-ras (89, 90). In quiescent cells, Ras is bound to GDP, however upon
stimulation by growth factors such as EGF, Ras becomes bound to GTP and is in
an active form (84). Ras then phosphorylates and recruits Raf kinase to the cell
membrane, allowing its homo- or hetero- dimerization, leading to its activation.
On the other hand, Raf activation can be inhibited by phosphatases 2A (PP2A)
(82, 88). Three Raf genes are found in mammals: A-Raf, B-Raf and C-Raf
(Raf1), with c-Raf being more ubiquitously expressed (88, 90). Raf consists of an
N-terminal regulatory domain and a C-terminal kinase domain. Within the Nterminal regulatory domain are two conserved regions (CR) referred to as CR1
and CR2. The Ras binding domain and a cysteine rich domain are located in
CR1. CR2 is a serine/threonine rich domain; and the third conserved domain
CR3 is located in the kinase domain and is required for Raf activity. Removal of
the regulator domain leads to an oncogenic kinase referred to as Raf-BxB (88).
Once Raf is activated, it phosphorylates and activates MEK1 and MEK2
(MEK1/2) (88, 90). The three different Raf isoforms can all phosphorylate and
activate MEK1/2 to varying degrees, with B-Raf being the strongest and A-Raf
the weakest (88). At the amino acid level, MEK1 and MEK2 are 79% identical in
humans. Once MEK1/2 are activated, they then phosphorylate and activate
ERK1/2 (90).
In humans, ERK1 and ERK2 are 84% identical at the amino acid level
(90). MEK1/2 which can phosphorylate both threonine and tyrosine residues,
phosphorylates ERK1/2 via a threonine-glutamic acid-tyrosine motif within the
ERK1/2 activation loop (88). ERK1/2 are predominantly found in the cytosol in
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quiescent cells. However following serum stimulation, translocation to the
nucleus increases (91). In vivo experiment showed that while ERK2 absence
from the cells leads to embryonic lethality (90), ERK1 deficient mice only showed
minor phenotypic changes. They were viable, fertile and showed normal size.
However, maturation of the thymocytes was reduced by approximately 50%. In
addition, there was no difference between MEFs from wild type and ERK1
deficient mice in terms of growth rate (92). Among many other cellular processes,
ERK1/2 is important in regulating cell migration shown by several research
efforts using either dominant-negative ERK or inhibition of the ERK-MAPK
pathway using siRNA techniques (86, 93, 94). ERK1/2-mediated phosphorylation
of its substrates, such as myosin light chain kinase (MLCK), caplains and focal
adhesion kinase (FAK) and the nuclear ETS-domain containing protein, ELK-1,
were particularly shown to be involved in mediating cell migration (93, 94).

Deregulation within the ERK-MAPK Pathway
Deregulation of the ERK1/2 pathway is involved in various pathologies
including neurodegenerative diseases, developmental diseases, diabetes, and
cancer (85). Over activation of the ERK1/2 pathway can lead to the induction of
cellular processes seen in the hallmarks of cancer. These processes include
immortalization, growth factor independent growth, insensitivity to growth
inhibitory signal, invasion and metastasis, angiogenesis and evading apoptosis
(88). Deregulation of the ERK-MAPK pathway occurs in approximately 30% of all
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cancers, including cancer of the pancreas, colon, thyroid, lung and melanoma.
Mutations occurring in the upstream components of the pathway leads to
constitutive activation of the phosphorylation cascade (85, 88, 95). Early stages
that lead to the activation of ERK1/2 are affected in most cancers, e.g tyrosine
kinase receptor overexpression, mutation in tyrosine kinase receptor that leads to
its continuous activation, and mutations in Ras or B-Raf (84, 88, 95). The Ras
genes are frequently found to be mutated in several human tumors. Point
mutations in the Ras genes result in a protein product with alterations in the
amino acid at critical positions: 12, 13 or 61 (89). Mutations at these codons lead
to constitutive Ras activation by preventing efficient GTP hydrolysis (95).
Mutations upstream of ERK1/2 leads to eventual over activation of the ERKMAPK pathway, and further over expression of substrates either in the nucleus or
the cytoplasm that may promote the processes involved in cancer initiation,
progression and metastasis. (84)
The FDA has approved approximately 10 inhibitors of protein kinases, and
over 100 agents that target kinases which are under clinical investigation (84).
Numerous research efforts have been focused on inhibitors that target the ERKMAPK pathway, since it was shown that ERK-MAPK signaling promotes cell
proliferation, cell survival and metastasis (84). The MEK inhibitors, such as
PD98059 and U0126, even though highly specific, lack pharmaceutical
properties needed for clinical treatment in patients (84). Therefore, there still
exists a need for research that will help to develop drugs that will target ERKMAPK pathway as well as ERK1/2 substrates.
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Conclusion and Central Hypothesis
HDAC6 has been implicated in cell motility through its ability to
deacetylate its cytoplasmic substrates, thereby affecting the MT and actin
network. Like other HDACs, HDAC6 can also be regulated by PTM such as
phosphorylation to either enhance or hinder its deacetylase activity. HDAC6
expression is up-regulated in many cancer tissues compared to their normal
tissue counterparts; and animal models have indicated that HDAC6 enhances
tumor metastasis. Therefore, understanding the mechanisms through which
HDAC6 promotes cell motility and metastasis would be beneficial to the
development of pharmacological agents. Based on the published literature and
our preliminary data, we hypothesized that 1) Phosphorylation of HDAC6 at
serine1035 promotes cell migration through deacetylation of its substrates and 2)
HDAC6 promotes cell migration in vivo
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FIGURE

Figure 1.1. A representation of human HDAC6 structure consisting of two
deacetylase domains (DAC1 and DAC2), the cytoplasmic anchoring motif (SE14), and the ubiquitin carboxyl-terminal hydrolase-like zinc finger (ZnF-UBP)
domain. NES and NLS represent nuclear export signals and a nuclear
localization signals, respectively.
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CHAPTER TWO
HDAC6 SERINE-1035 IS PHOSPHORYLATED BY ERK1 DURING
ACTIVATION OF THE ERK-MAPK PATHWAY

Abstract
Histone deacetylase 6 (HDAC6) is a class IIb histone deacetylase family
member. HDAC6 is mainly localized to the cytoplasm but can also be
translocated to the nucleus in some instances. Previous studies have reported
that HDAC6 is a phospho-protein and identified the kinases involved. In this
study, we used mass spectrometric analysis and identified HDAC6 serine-1035
as a phosphorylation site located within an extracellular signal regulated kinase
(ERK1/2) recognition motif. In vitro and in vivo assay further proved that ERK1
phosphorylates HDAC6 at this site. Using a series of active kinases we show that
activation of the ERK-MAPK signaling axis promotes phosphorylation of HDAC6
at this site. On the other hand, use of dominant-negative kinases, HDAC6
unphosphoryation mimetic HDAC6(S1035A), and MEK inhibitors showed
diminished phosphorylation of HDAC6, indicating that HDAC6 serine-1035 is a
major ERK1 phosphorylation site of HDAC6. Since the ERK-MAPK pathway is a
key target of numerous signaling events, both ERK1/2 and HDAC6 specific
inhibitors may prove beneficial for future research directions.
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Abbreviations
ATP, adenosine triphosphate; DN, dominant negative; EGFR, epidermal
growth factor receptor; ERK1/2, Extracellular signal-regulated kinase 1 and 2;
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hemagglutinin; HAT, Histone acetyltransferase; HDAC, histone deacetylase;
MAPK, mitogen activated protein kinase; MEK, MAP/ERK kinase ;PKCα, protein
kinase C alpha; sir2, silent information regulator 2; NP-40, nonyl
phenoxypolyethoxyethanol-40.

Introduction
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are
enzymes involved in modifying core histones through the addition or removal of
acetyl group from the lysine residue on histone tails (1). Acetylation of core
histones usually results in transcriptional activation, whereas deacetylation of
core histones causes transcriptional repression (1). HDACs are grouped into four
classes based on phylogenetic analysis and sequence homology. They are class
I (HDACs 1, 2, 3 and 8), class II (HDACs 4, 5, 6, 7, 9, and 10), class IV (only
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HDAC11) and the silent information regulator 2 (sir2) related family which
represents the class III HDACs consisting of the sirtuins 1-7 (1-3). Classes I, II
and IV require Zn2+ as a cofactor to be active, while class III HDACs bearing no
sequence similarity to class I, II and IV need NAD+ as a cofactor (1). Class I
HDACs are ubiquitously expressed in many cell types and are found almost
exclusively in the nucleus. However, the expression pattern of class II HDACs is
more restricted and they are able to shuttle between the nucleus and the
cytoplasm in response to cellular signals (4-7). Apart from histones, it is well
known that HDACs also modify non-histone proteins which in turn regulate the
functionality of those proteins (8).
HDAC6 which belongs to the class IIb HDACs is unique among HDACs in
that it is the only HDAC that contains a complete duplication of the large class I/II
HDAC homology domain. HDAC6 consists of both a nuclear export signal
located in the N-terminus and a cytoplasmic anchorage motif known as SE-14
motif in the C-terminus (9, 10); and a zinc finger motif, which binds to mono- and
poly-ubiquitin chains (10, 11). HDAC6 is recognized for deacetylating
cytoplasmic proteins, including α-tubulin (12, 13), cortactin (14), and HSP90 (15).
HDAC6 associates with microtubules through its HDAC domain and is capable of
deacetylating α-tubulin at lysine 40 both in vivo and in vitro (13). It is generally
believed that HDAC6 deacetylation of microtubules and cortactin influences both
microtubule-dependent and actin-dependent cell motility, respectively (12, 14).
Recently, phosphorylation sites within HDAC6 as well as the kinases that
are responsible for phosphorylating these sites have been shown. Glycogen
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synthase kinase-3β (GSK-3β) is one such kinase. GSK-3β phosphorylates
HDAC6 at the serine-22 site located in HDAC6’s N-terminus (16). Studies also
suggest that GSK-3β enhances HDAC6 deacetylase activity towards α-tubulin
(16). HDAC6 can also be phosphorylated by Aurora A kinase, a centrosomal
kinase involved in regulating mitotic entry (17). Phosphorylation of HDAC6 by
Aurora A enhances HDAC6’s ability to deacetylate acetylated α-tubulin to
promote ciliary disassembly, but the phosphorylation site for this kinase remains
to be identified (17). Recently, the G protein-coupled receptor kinase 2 (GRK2)
was shown to phosphorylate HDAC6 and stimulate its α-tubulin deacetylase
activity (18). In addition to α-tubulin, phosphorylation of HDAC6 also alters its
deacetylase activity toward other substrates, such as β-catenin. As reported by
Zhu et al., protein kinase C alpha (PKCα) enhances HDAC6 deacetylase activity
towards β-catenin, and further regulates its nuclear translocation and promoter
binding (19). Besides the serine/threonine kinases, tyrosine kinases such as
epidermal growth factor receptor (EGFR) kinase also phosphorylates tyrosine
570 within the HDAC6 C-terminal deacetylase domain, which results in a
decrease in the deacetylase activity of HDAC6, an increase in α-tubulin
acetylation and altered EGFR trafficking (20). Overall, numerous kinases target
HDAC6 at different amino acid residues to regulate its activity towards its
substrate and ultimately influence cell motility and other cellular functions.
Extracellular signal-regulated kinase 1 and 2 (ERK1/2) are related proteinserine/threonine kinases from the mitogen activated protein kinase (MAPK)
family that participate in the EGFR-Ras-Raf-MEK-ERK1/2 signal transduction
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cascade (21). ERK1/2 catalyzes the phosphorylation of numerous substrates
including those of the nucleus, cytoplasm, cytoskeletal proteins and protein of the
nuclear complex (21). Downstream targets of ERK1/2 are involved in many
biological processes including cell adhesion, cell cycle progression, cell survival,
differentiation, metabolism, proliferation, transcription, and cell migration (21, 22).
Here, we have identified the cytoplasmic deacetylase HDAC6 as a novel ERK1
substrate. Our results suggest that HDAC6 associates with ERK1/2 both in the
nucleus and the cytoplasm, and that activation of the EGFR-Ras-Raf-MEKERK1/2 signaling cascade promote phosphorylation of HDAC6 at serine 1035
within its C-terminus.

Results
LC-MS/MS Identifies Threonine-1031 and Serine-1035 of HDAC6 as
Phosphorylation Sites
In order to identify novel phosphorylation sites of HDAC6, 293T cells were
transduced with adenovirus HA-HDAC6-F (14) for 36 hours. The cells were then
lysed and HDAC6 was immunoprecipitated by anti-Flag antibodies. The
immunoprecipitates were resolved on SDS-PAGE, then followed by Coomassie
blue staining. The HDAC6 band was excised and subjected to liquid
chromatography-tandem mass spectrometry (LC-MS/MS) analyses. As shown in
Fig. 1A-C, the mass spectrometry analyses identified two novel phosphorylation
sites located in the C-terminal region of HDAC6, namely threonine-1031 (T1031)
and serine-1035 (S1035). The extent of HDAC6 phosphorylation on these two
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sites was also examined by quantitative mass spectrometry. The majority of
immunoprecipitated wild type HDAC6 was phosphorylated (82.5%) (Fig. 1D),
suggesting the importance of the T1031 and S1035 sites. Among these two sites,
S1035 is within the ERK1/2 optimal consensus motif (P-X-S/T-P) (23), whereas
T1031 is within the ERK1/2 minimal recognition motif (S/T-P) (Fig. 1E). In
addition, T1031 and S1035 were conserved among rat, mouse, dog and human,
but not drosophila and fish (Fig. 1E and data not shown). This suggests that
these sites are conserved in mammals. Although serine-1045(S1045) is also
located within an ERK1/2 recognition motif, the mass spectrometry analyses did
not reveal it as a phosphorylation site.

Threonine-1031 and Serine-1035 of HDAC6 are Phosphorylated by
ERK1 In Vitro
We next set out to determine whether ERK1/2 is indeed involved in
phosphorylating these sites. To this end, we used recombinant ERK1 and the Cterminal fragments of HDAC6 harboring wild type (WT) or mutants, whereby
Threonine(T) or serine(S) was mutated to alanine(A) (T1031A, S1035A,
T1031A/S1035A, S1045A) (Fig. 2A) to perform the in vitro kinase assays. Our
results showed that S1035 was a major phosphorylation site for ERK1 as was
evidenced by the disappearance of the phosphorylation signal when this site was
mutated from serine to alanine (Fig. 2B, lane 3). Mutation of the T1031 site to
alanine, exhibit a moderate decrease in the levels of phosphorylation (Fig. 2B,
lane 4 vs. lane 2), indicating that the T1031 site is not a major ERK1
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phosphorylation site. The results also showed that the phosphorylation of T1031
by ERK1 was dependent on S1035 phosphorylation, because in the double
mutant, HDAC6(816-1215)T1031A/S1035A, no phosphorylation signal was
observed (Fig. 2B, lane 5). Moreover, the phosphorylation signal of S1045A was
comparable to that of the WT (Fig. 2B, lane 6 vs. lane 2), indicating that S1045
was not phosphorylated by ERK1 in vitro. In addition, we also examined whether
another MAPK, p38, can phosphorylate the C-terminal region of HDAC6. Our
analyses indicated that the p38α kinase phosphorylated WT, as well as the
T1031A, S1035A and S1045A mutants of HDAC6 to similar levels. This suggests
that T1031, S1035 and S1045 are not p38α phosphorylation sites (data not
shown). Collectively, the mass spectrometry analyses and the in vitro kinase
assays have demonstrated that S1035 and T1031 can be phosphorylated by
ERK1 in vitro, whereas S1045 cannot be phosphorylated.

Serine-1035 of HDAC6 is Phosphorylated Through the EGFR-RASRAF-MEK-ERK Pathway In Vivo
After we determined that ERK1 phosphorylated HDAC6 in vitro, we next
asked whether the phosphorylation by ERK1 also occurred in vivo. Mouse
embryonic fibroblast (MEFs) were treated with MEK inhibitors, U0126 and
PD98059. Then immuno-precipitation experiments using phosphoserine/threonine antibodies were performed to assess the phosphorylation status
of HDAC6. In comparison to the control, both U0126 (10 µM) and PD98059 (100
µM) caused a significant decrease in phosphorylation of HDAC6 when ERK1/2
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was inhibited (Fig. 3A, lane 1 vs. lanes 2 and 3). To validate our results, an active
form of Ras (RasG12V) was employed to stimulate the Raf-MEK-ERK signaling
cascade. This allows the examination of whether activation of the ERK-MAPK
pathway is able to increase HDAC6 phosphorylation. At the same time a
dominant-negative (DN) form of MEK, MEK(K97A), was transfected into cells to
block the downstream ERK-MAPK pathway. As shown in Fig. 3B, active Ras
dramatically increased HDAC6 phosphorylation (lane 3 vs. 2), while DN-MEK
significantly decreased HDAC6 phosphorylation (lanes 4). Since ERK1/2 is the
sole substrate of MEK, the above results indicated that ERK1/2 is indeed
involved in phosphorylating HDAC6 in vivo.
We next examined whether HDAC6 phosphorylation is increased by
upstream kinases of ERK1/2. Since the ERK-MAPK pathway is well established,
we transfected a constitutively active c-RAF mutant c-RAF-BXB (24, 25) into
293T cells to activate endogenous ERK1/2. As shown in Fig. 4A, transfected cRAF-BXB activated downstream MEK and ERK1/2 kinases (lane 3 vs. lanes 1
and 2). HDAC6 phosphorylation was significantly increased in c-RAF-BXB
transfected 293T cells (lane 3 vs. lane 2), showing that HDAC6 was
phosphorylated in response to the activation of Raf-MEK-ERK pathway. We next
explored whether the upstream kinase EGFR increases HDAC6 phosphorylation
as well. As shown in Fig. 4B, active EGFR, EGFR (vIII), was able to elevate
ERK1/2 activity and modestly increase HDAC6 phosphorylation. Altogether, we
have shown that EGFR-Ras-Raf-MEK-ERK-MAPK signaling targets HDAC6 in
vivo.
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The Serine-1035 Site of HDAC6 is a Major ERK Phosphorylation Site
Both the mass spectrometry analysis (Fig. 1D) and the in vitro kinase
assay (Fig. 2) indicated that S1035 of HDAC6 is a predominant phosphorylation
site. We then examined whether activation of the ERK-MAPK pathway
phosphorylates HDAC6 at S1035 in vivo. We used HDAC6 WT, as well as
S1035A mutants of HDAC6 in these studies. As shown in Fig. 4C, active Ras
(G12V), or active MEK(S218/222D) dramatically increased phosphorylation of
wild type HDAC6 (lanes 4 and 6 vs. lane 2) but not HDAC6 (S1035A) mutant
(lanes 5 and 7 vs. lane 2). This result strongly supports that S1035 is a major
phosphorylation site of HDAC6 targeted by ERK1/2. To further confirm whether
ERK1/2 phosphorylates HDAC6 at S1035, 293T cells were transiently
transfected with plasmids for empty vector, HA-HD6-F, HA-HD6(S1035A)-F or
HA-HD6(S1035D)-F in the absence or presence of c-RAF-BXB. As represented
by Figure 4D, mutation of HDAC6 at the S1035 site decreased HDAC6
phosphorylation dramatically. Moreover, since c-RAF-BXB could not increase the
phosphorylation of HA-HD6(S1035A)-F and HA-HD6(S1035D)-F, this suggests
that activation of the Raf-MEK-ERK signaling pathway mainly targets the S1035
site of HDAC6 in vivo.
We next employed epidermal growth factor (EGF) to activate the ERKMAPK pathway and observed HDAC6 phosphorylation. 293T cells were
transiently transfected with WT HDAC6 or S1035A mutant followed by treatment
with EGF. As illustrated in Fig. 5, EGF significantly induced phosphorylation of
WT HDAC6, but not the S1035A mutant, suggesting that EGF-induced HDAC6
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phosphorylation is via S1035. Together, these data provide compelling evidence
that HDAC6 C-terminal S1035 is a major phosphorylation site in vivo.

ERK1/2 Associates with HDAC6 both in the Cytoplasm and the
Nucleus
Other HDACs including HDAC6 have been shown to interact with kinases
involved in their phosphorylation (18, 26). Since we determined that HDAC6 can
be phosphorylated by ERK1, we wonder whether there is a physical interaction
between ERK1 and HDAC6, and whether HDAC6 is involved in regulating
phospho ERK1/2 expression. In addition, we observed that MEFs cells
expressing HDAC6, exhibits reduced phospho kinases compared to their HDAC6
null counterpart (Fig. 6). To determine whether HDAC6 is associated with
ERK1/2, bacterial expressed glutathione S-transferase (GST) tagged full length
or deletions of HDAC6 were used to pull down endogenous ERK1/2 in HeLa S3
nuclear and cytoplasmic fractions, which were prepared as described in Dignam
et al. (27). As shown in Fig. 7, HDAC6(1-503) and HDAC6(448-840) shows
binding in both the nuclear and cytoplasmic fraction. However, reduced
interaction was observed between ERK1/2 and HDAC6(840-1215), suggesting
that ERK1/2 effectively binds to HDAC6 N-terminal catalytic domain 1 (DAC1) or
domain 2 (DAC2), respectively. We further try to determine whether HDAC6
deacetylase function is involved in the regulation of phospho ERK1/2 protein
expression. We used transfected 293T cells expressing double mutant of HDAC6
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catalytic domains, as well as HDACi treatment of normal lung cells, then
observed protein expression of phospho-ERK1/2 and total-ERK1/2. In both
instances we did not observe any changes in phospho-ERK1/2 expression (data
not shown). Further studies are needed to decipher how HDAC6 may regulate
ERK1/2 phosphorylation.

Discussion
The HDACs family members are widely regulated by post-translational
modification such as phosphorylation (28-32). HDAC6 is no exception to
modification by phosphorylation. Previous studies have shown that HDAC6 can
be phosphorylated by kinases such as GSK-3β, EGFR kinase, Aurora A and
GRK2 (16-18, 20). In this study, we have demonstrated that HDAC6 is a novel
substrate for ERK1. We have also identified S1035 as a major ERK1
phosphorylation site in HDAC6 C-terminal region. Our results suggest that
activation of the EGFR-Ras-Raf-MEK-ERK signaling axis induces HDAC6
phosphorylation at S1035 as depicted by Fig 8. Apart from the S1035 site, we
have also identified T1031 as a phosphorylation site in HDAC6 (Fig. 1 and 2). As
shown in Fig.4C, D, and Fig. 5, HDAC6(S1035A) mutant could not efficiently be
phosphorylated by active Ras, active MEK, active Raf or by the use of EGF.
These results suggest that the S1035 site is the major site targeted by ERK1.
Furthermore, the results suggest that the T1031 site may not be important for
ERK-mediated phosphorylation. Nevertheless, given the proximity of T1031 and
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S1035, we cannot rule out the possibility that T1031
phosphorylation/dephosphorylation influences HDAC6 function. Future studies
employing T1031 phosphorylation or dephosphorylation mimicking single mutant
(T1031A and T1031D) or T1031 and S1035 double mutants (T1031A/S1035A
and T1031D/S1035D) are warranted.
ERK1/2 regulates a wide variety of processes through their actions on
downstream targets. In the cytoplasm alone over 50 substrates have been
identified, including cytoskeletal protein regulators and signaling molecules (21).
In quiescent cells ERK1/2 are found predominantly in the cytosol, but following
serum stimulation its migration to the nucleus increases (33). Because HDAC6 is
able to translocate form the cytoplasm to the nucleus (34), and since ERK1/2
phosphorylate its target both in the cytoplasm and the nucleus (21), it would be
interesting to determine whether HDAC6 is phosphorylated both in the
cytoplasm, as well as in the nucleus. We have already shown that ERK1/2 is able
to bind HDAC6 both in the cytoplasm as well as in the nucleus (Fig. 7). Using
HDAC6 WT, as well as the S1035 unphosphorylated/phosphorylated mimetics,
fractionation and immunofluorescence studies were unable to determine any
differences in HDAC6 protein localization in the cytoplasm or the nucleus (data
not shown). Since HDAC6 interacts with ERK1/2, it is conceivable to speculate
that HDAC6 could also regulate ERK1/2. It is possible that HDAC6 modulates
ERK1/2 acetylation, to affect its phosphorylation and subsequently its enzymatic
activity.
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Location of phosphorylation sites in other class I and II HDACs affects
their nucleocytoplasmic shuttling, as well as their interactions with other proteins.
HDAC5 was shown to be phosphorylated by cyclic adenosine monophosphate
/protein kinase A (cAMP/PKA) which prevents it from leaving the nucleus (35).
Increased accumulation of HDAC5 in the nucleus enhances association with
other binding partners such as HDAC3 (36). Previously HDAC4, another class II
HDAC family member, was reported to be a target of ERK1/2 as well. HDAC4 is
phosphorylated by ERK1/2 in vitro as well as in cells. In addition, HDAC4
enhanced localization in the nucleus was associated with higher kinase activity of
ERK1/2 (26). Recently we were able to generate the anti phospho-serine-1035
HDAC6 site specific antibody. With further optimization we hope to determine
subcellular distribution of ERK1/2-mediated phosphorylation of HDAC6. We also
hope to identify any additional substrates or binding partners of HDAC6 that may
be involve in cellular processes that are affected by HDAC6.
The ERK-MAPK pathway is involved in promoting many cellular processes
involved in the hallmark of cancer such as proliferation, apoptosis, immune
response, angiogenesis, and metastasis (37). Deregulation of the ERK-MAPK
pathway therefore contributes to many disease states including cancer (38). The
ERK-MAPK pathway is of major interest because of the activating mutations
found upstream particularly at EGFR, Ras and Raf. It is therefore a key target for
anticancer therapy (38, 39). However, targeting Ras has proven unsuccessful.
Likewise, Raf and its downstream target also presents with challenges including
acquired resistance (39). Previously, it was shown that HDAC6 expression is
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induced upon oncogenic Ras transformation, and that HDAC6 is involved in
promoting transformation and tumorigenesis (40). This study revealed HDAC6 as
a novel substrate of ERK1. Since both the ERK pathway and HDAC6 were
shown to be involved in processes in cancer progression, both ERK1/2 and
HDAC6 represent effective drug target that can be considered for cancer
therapy.

Experimental Procedures
Plasmids, Antibodies, Reagents, and Cell lines
Double tagged HDAC6 (HA-HDAC6-F) is described in the reference (14).
The point mutations on this construct were created by QuikChange® XL SiteDirected Mutagenesis Kit (Stratagene). For HA-HDAC6(S1035A)-F, the primers
used are : 5’ CCACCAGACCCCCCCAACCGCACCTGTGCAG 3’ and
5’ CTGCACAGGTGCGGTTGGGGGGGTCTGGTGG 3’.
For HA-HDAC6(S1035D)-F, the primers used are:
5’ CCACCAGACCCCCCCAACCGACCCTGTGCAG 3’ and
5’ CTGCACAGGGTCGGTTGGGGGGGTCTGGTGG 3’.
GST-HDAC6(816-1215) plasmid was constructed by inserting the PCR-amplified
HDAC6 sequence derived from HA-HDAC6-F into the SalI/NotI sites of pGEX4T1 vector using the following primers: SalI/HDAC6,
5’ AGTCGACGGGCCCTGGCCTCAATCACTG 3’ and NotI/HDAC6,
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5’ AGCGGCCGCTTAGTGTGGGTGGGGCATATCC 3’. Point mutations of
HDAC6 in this construct were created using the following primers: for
GST-HDAC6(816-1215) S1045A,
5' CACCCCAGATAGCTCCCAGTACACTGATTG 3' and
5' CAATCAGTGTACTGGGAGCTATCTGGGGTG 3'; for
GST-HDAC6(816-1215) T1031A/S1035A,
5’ CCACCAGGCCCCCCCAACCGCACCTGTGCAG 3’ and
5’ CTGCACAGGTGCGGTTGGGGGGGCCTGGTGG 3’; for
GST-HDAC6(816-1215)T1031A,
5’ CCACCAGGCCCCCCCAACCTCACCTGTGCAG 3’ and
5’ CTGCACAGGTGAGGTTGGGGGGGCCTGGTGG 3’; for
GST-(816-1215)S1035A, the primers are the same as used for generation of
HA-HDAC6(S1035A)-F. The PCR cycle was as follows: 95°C, 1 min; followed by
95°C, 50 sec; 60°C , 50 sec; 68°C, 20 min for 25 cycles and then 68°C, 30 min.
GST-HD6, GST-HD6(1-503), GST-HD6(448-840) and GST-HD6(840-1215)
plasmids were generated by PCR. Detailed information is available upon request.
C-RAF-BXB was described in (25), HA-Ras(G12V), HA-MEK(K97A) and HAMEK(S218/222D) were kind gifts from Dr. Jie Wu. EGFR (vIII) plasmid was
described by Shen et al. (24).
Anti-HDAC6 (H300) and anti-EGFR (1005) antibodies were purchased
from Santa Cruz Biotechnology. Anti-phospho serine/threonine antibody was
purchased from BD Bioscience. Anti-HA antibody was purchased from Covance.
Anti-β-tubulin antibody and lipofectamine 2000 reagent were purchased from
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Invitrogen. Anti-Flag antibody was purchased from Sigma. Anti-ERK1/2 antibody
(#9102), anti-phospho-ERK1/2 (Thr202/Tyr204) antibody (#9101), anti-c-RAF
(#9422), anti-phospho-c-RAF antibody (Ser338) (56A6) (#9427), anti-phosphoMEK1/2 (Ser217/221) antibody (#9121), human EGF, and recombinant Erk1
kinase (#7416) were purchased from Cell Signaling Inc. U0126 and PD98059
were purchased from CALBIOCHEM.
HDAC6 wild type and knockout MEFs, and 293T cells, were cultured in
DMEM medium with penicillin (100 U/ml), streptomycin (100 mg/ml) and 10%
fetal bovine serum (FBS) and incubated at 37ºC with 5% CO2.

In Vitro Kinase Assay
GST fusion proteins containing C-terminus of wild type or mutant of
HDAC6 as shown in Fig. 2A were incubated with recombinant ERK1 (Cell
Signaling, Inc.) in the presence of 5 µCi of [γ-32P]ATP, 10 µM ATP and 1X kinase
buffer (10 mM Tris, pH 7.4, 150 mM NaCl,10 mM MgCl2 ,0.5 mM Dithiothreitol
(DTT) ) for 30 min at 30 °C. Reactions were terminated by adding SDS loading
buffer followed by heating at 100 °C for 5 mins. Proteins were separated on 6%
SDS polyacylamide gel, and phosphorylated proteins were visualized by
autoradiography.
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Immunoprecipitation and Immunoblotting
For immunoprecipitations, cells were lysed in LS buffer (PBS [pH 7.5],
10% glycerol, 0.1% NP-40, and protease inhibitor cocktail). Lysates were
incubated with protein A or protein G agarose for 2 hours for pre-clearing prior to
incubation with the indicated primary antibodies for 12 h at 4°C. Immunocomplexes were collected, washed four times in lysis buffer, and resolved by
SDS-PAGE. For immunoblotting, samples were transferred to nitrocellulose
membranes that were then probed with the indicated antibodies. Bound
antibodies were detected using a Chemiluminescent Detection Kit (Pierce).
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Figure.2.1. Threonine-1031 and Serine-1035 are Phosphorylated in HDAC6.
The peptide was detected at 32.6 minutes in the total ion chromatogram (TIC)
(A), with mass-to-charge ratio 1068.5189, triply charged, and representing an
error of 6.8 ppm (B). The tandem mass spectrum matched the following
sequence, HQTPPTSPVQGTTPQISPSTLIGSLRTLE, indicating that T1031 and
S1035 (highlighted in red) were phosphorylated; the detection of b , y and y is
3

22

23

consistent with this localization (C). The assignment was made with Mascot with
a score of 50 and Sequest XCorr 5.62. Analysis showing extracted ion
chromatograms (EIC) for peptides containing both phosphorylated S1035 and
unmodified S1035 were extracted using Xcalibur 2.0(Thermo). The peak areas
under the curves were used to calculate the percentage of phosphorylation (D).
Upper panel: The consensus ERK1/ERK2 recognition motif. Lower panel: A
stretch of HDAC6 amino acid sequence showing the conservation of mass
spectrometry analyses identified two ERK1/ERK2 sites (T1031 and S1035) and a
putative ERK1/ERK2 site (S1045) among rat, mouse, dog and human (E).
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Figure.2.2. HDAC6 is Phosphorylated by ERK1 In Vitro at Threonine-1031
and Serine-1035. (A) The diagram of full length and C-terminus of HDAC6 with
putative phosphorylation sites. (B) Upper panel: In vitro kinase assays were
performed with the indicated substrates and recombinant ERK1 as described in
the Methods section. The reaction mixtures were separated on 6% SDS-PAGE
and analyzed by autoradiography. The amount and purity of proteins used in the
kinase assays were shown on a coomassie blue stained gel (lower panel)
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Figure.2.3. HDAC6 Phosphorylation is Targeted by ERK-MAPK Pathway In
Vivo. (A) HDAC6 phosphorylation was decreased by MEK inhibitor treatment.
MEFs were treated with MEK inhibitor U0126 or PD98059 with indicated
concentration for 1 hr. Endogenous HDAC6 was immunoprecipitated (IP) by antiHDAC6 antibodies The phosphorylation status of HDAC6 was measured by
immunoblotting (IB) using anti-phospho-serine/threonine antibodies. The blot was
then stripped and reprobed with anti-HDAC6 antibodies. Anti-P-ERK and anti-TERK Western blotting analyses were also performed as indicated. (B) Rasinduced HDAC6 phosphorylation was attenuated by dominant-negative MEK.
293T cells were transfected using indicated plasmids. HA and Flag double
tagged HDAC6 was IP by anti-HA agarose beads. Phosphorylation of HDAC6
was examined by IB with anti-P-Ser/Thr antibodies. The same membrane was
then stripped and blotted with anti-HA antibodies to detect the IP efficiency of
HDAC6, HA-MEK(K97A) and HA-Ras(G12V). Anti-P-ERK, anti-T-ERK and antiβ-tubulin western blotting was also performed.
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Figure.2.4. HDAC6 Serine-1035 is a Major Phosphorylation Site Targeted by
EGFR-RAS-RAF-MEK-ERK Pathway In Vivo. (A) Active c-RAF (c-RAF-BXB)
increased HDAC6 phosphorylation levels in vivo. 293T cells were transiently
transfected with empty vector, HA-HD6-F alone or HA-HD6-F with c-RAF-BXB.
Forty eight hours post transfection, cells were harvested and lysed.
Phosphorylation of HA-HD6-F was detected by IP Western as indicated. The IP
efficiency was examined by Western blotting with anti-HA antibody. The activity
and expression of c-RAF-BXB was examined by Western blotting with anti-P-cRAF antibody and anti-T-c-RAF antibody, respectively. The expression and
activity of MEK and ERK were also examined by the indicated antibodies. Equal
loading of protein was examined by anti-β-tubulin Western blotting analysis. (B)
Active EGFR increased HDAC6 phosphorylation levels in vivo. 293T cells were
transiently transfected with indicated plasmids. Phosphorylation of HA-HD6-F
was detected by IP Western as indicated. The IP efficiency was examined by IB
with anti-HA antibodies. The expression and activity of EGFR was examined by
Western blotting with anti-EGFR and anti-P-ERK antibodies. Anti-T-ERK and
anti-β-tubulin Western blotting analyses were also carried out. (C) S1035 site is a
major phosphorylation site of HDAC6. 293T cells were transiently transfected
with indicated plasmids. Following transfection, cell lysate was immunoprecipitated using anti-HA beads. Phosphorylation status of HDAC6 (P-HDAC6)
was determined using anti-phospho-serine/threonine Western blotting analysis.
The same blot was then stripped and reprobed with anti-HA antibody to examine
the IP efficiency as well as the levels of HA-MEK(S218/222D) and HARas(G12V). The anti-P-ERK, anti-T-ERK, and anti-β-tubulin Western blotting
analyses were also carried out. (D) S1035 site is a major phosphorylation site of
HDAC6. Upper panel: 293T cells were transiently transfected with indicated
plasmids. Following transfection cell lysate was immuno-precipitated using antiHA beads. Phosphorylation status of HDAC6 (P-HDAC6) was determined with
anti-phospho-serine/threonine Western blotting analysis. IgG heavy chain (IgGH) was also indicated. Lower panel: The same blot was stripped and reprobed
with anti-HA antibody.
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Figure.2.5. EGF-Induced Phosphorylation of HDAC6 Wild Type but not
Unphosphorylation Mimicking Mutant. EGF increased HDAC6
phosphorylation levels in vivo. 293T cells were transiently transfected with empty
vector, HA-HD6-F alone or HA-HD6(S1035A)-F. Following 24 hrs post
transfection, cells were serum starved overnight and treated with 50 ng/ml EGF
for the indicated times. Phosphorylation of HA-HD6-F or HA-HD6(S1035A)-F was
detected by IP Western as indicated. The IP efficiency was examined by Western
blotting using anti-HA antibody. The activity of EGF was examined by Western
blotting with anti-P-ERK1/2 antibody and anti-T-ERK1/2 antibody. Equal loading
of protein was confirmed using anti-β-tubulin antibody.
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Figure.2.6. Phospho-ERK1/2 Protein Expression is Upregulated in HDAC6
Null MEFs Compared to HDAC6 Wild Type Counterpart. Total protein extracts
were prepared from HDAC6 wild type and HDAC6 null MEFs. Protein extracts
were analyzed by western blotting analyses.

77

Figure.2.7. ERK1/2 Interacts with HDAC6. (A) Representative of HDAC6 fulllength and HDAC6 deletion constructs. (B) GST beads or GST beads bound
proteins generated from each of the constructs were incubated with HeLaS3
nuclear or cytoplasmic fraction and GST pull-down assays were performed
followed by anti-ERK1/2 Western blotting analyses. Protein expression was
shown by coomassie blue staining.
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Figure.2.8. The working model of HDAC6 phosphorylation following
activation of ERK-MAPK signaling cascade.
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CHAPTER THREE
ERK1-MEDIATED PHOSPHORYLATION OF HDAC6 AFFECTS
DEACETYLATION OF HDAC6’s SUBSTRATES

Abstract
The predominantly localized cytoplasmic deacetylase HDAC6 is involved
in many biological processes within the cell. HDAC6 promotes its function
primarily through the deacetylation of its non-histone proteins. We used
phosphorylation and unphosphorylation mimetics of HDAC6 by mutating serine1035 to alanine or aspartic acid respectively to determine how HDAC6
deacetylase function towards its substrate is affected. We showed that
phosphorylation of HDAC6 at serine-1035 does not affect HDAC6 histone
deacetylase function or its deacetylase function towards cortactin. However, the
unphosphorylation mimicking mutant of HDAC6 hinders HDAC6’s ability to
deacetylate two of its cytoplasmic substrates α-tubulin, and β-catenin.
Interestingly, we observed that HDAC6 phosphorylation mimicking mutant
enhances deacetylation of β-catenin similar to that observed in HDAC6 wild type.
Since the ERK1/2 pathway activation enhances HDAC6 phosphorylation and
affects HDAC6 function, inhibitors of both ERK1/2 and HDAC6 may prove
beneficial for future research directions.
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Keywords
Deacetylation, phosphorylation, α-tubulin, cortactin, β-catenin.

Abbreviations
A, alanine; aspartic acid, D; CBP, creb binding protein; CK1, casein kinase
1; GSK-3β, glycogen synthase kinase 3β; HDAC6, Histone deacetylase 6; HAT,
histone acetyltranferase; PP2A, protein phosphatase 2A; TDAC, tubulin
deacetylase; TSA, trichostatin A.

Introduction
Historically, the HDACs were known for modifying histones with resultant
transcriptional repression. However, more and more HDACs substrates are
emerging with involvement in numerous non-histone cellular regulations (1, 2).
HDAC6 belongs to class IIb classic HDAC family (1). Although HDAC6 is found
primarily in the cytoplasm, it is also capable of nucleo-cytoplasmic shuttling like
all the other class II HDAC family members (3). Indeed HDAC6 was observed in
the nucleus during arrest in cell proliferation (4).
Since HDAC6 is predominantly cytoplasmic, it is not surprising that it is
associated with the microtubule network, which influences cell motility through
deacetylation of its cytoplasmic substrate α-tubulin (5, 6). HDAC6 also localizes
to the peri-nuclear and leading edge subcellular region of cells in association with
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p150glued containing motor complex (5). HDAC6 associates with the C-terminal tail
of β-tubulin and is recruited to the α/β tubulin dimers or microtubules (6).
HDAC6’s subcellular localization in close proximity to α-tubulin allows HDAC6 to
deacetylase α-tubulin on its lysine-40 residue (6).
The phospho-protein cortactin is a multi-domain protein that binds to the
actin network through F-actin (7). Cortactin association with the actin network
has implication in many processes of the cell, including cell migration, invasion,
neuronal morphogenesis, and tumor cell metastasis (7). Cortactin also promotes
lamellipodia formation and cell adhesion, which are all processes involved in cell
movement (7). Cortactin function and interaction with its binding partners can
also be affected by phosphorylation (7, 8). Phosphorylation of cortactin was
determined to be important for podosomes and invadopodia formation, which are
all structures needed for cell invasive potential (7). Cortactin can be deacetylated
by two different HDAC family members, HDAC6 and SIRT1 (9, 10). In both
cases, deacetylation of cortactin by either of the two HDACs promoted cell
migration (9, 10). In addition to cell migration, deacetylation of cortactin by
HDAC6 is important in regulating angiogenesis both in vitro and in vivo, and
vessel formation in zebrafish (11).
β-catenin is another cytoplasmic substrate of HDAC6 (12). β-catenin
functions as a key effector in the canonical Wnt pathway, which is a conserved
pathway that participates in regulating animal development from cnidarians to
mammals (13). β-catenin is also part of the cadherin-based cell-cell connection
located on the cytoplasmic side of the cell membrane (14). β-catenin binds to the
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cytoplasmic domain of type I cadherin and is essential in linking cadherin to the
actin cytoskeleton through interaction with α-catenin (14). β-catenin-mediated
activation of the Wnt pathway leads to Wnt specific gene transcriptional
activation, which regulates cell fate (13). Activation of Wnt pathway signaling
controls the levels of cytoplasmic free β-catenin, by preventing β-catenin
degradation by the destruction complex (13). The destruction complex consists of
scaffold protein axin and APC, glycogen synthase kinase 3β (GSK-3β), casein
kinase 1(CK1), and protein phosphatase 2A (PP2A) (13). Free β-catenin in the
cytoplasm is recognized by Axin and APC of the destruction complex. β-catenin
serine-45 is then phosphorylated by CK1α, priming phosphorylation of additional
sites such as threonine-41, serine-37 and serine-33 by GSK-3β (15). Once
phosphorylated, β-catenin associates with the ubiquitin machinery and is
targeted for degradation (13, 15). Previous studies have also associated HDAC6
with β-catenin. In the presence of epidermal growth factor (EGF) stimulation,
HDAC6 translocates from the cytoplasm to the caveolae membrane where it
associates with and deacetylates β-catenin at lysine-49 residue (12). β-catenin
deacetylation reduces its phosphorylation on serine-45 and hence its
degradation, and allows β-catenin nuclear translocation (12).
In this study we used unphosphorylation and phosphorylation mimetics of
HDAC6 serine-1035 sites to investigate the functional consequences of
phosphorylated HDAC6. Our results show that mutation of HDAC6 at the serine1035 site differentially affects HDAC6 ability to deacetylate its substrates.
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Results
Mutation of HDAC6 at Serine-1035 does not Affect HDAC6 Histone
Deacetylase Activity
We previously determined that ERK1 phosphophorylates HDAC6 both in
vitro and in vivo. Since histones are known nuclear substrates of HDACs (16), we
set out to determine whether ERK-mediated phosphorylation of HDAC6 at
serine-1035 is capable of affecting its deacetylase activity towards core histones.
We used unphosphorylation and phosphorylation mimicking mutants of HDAC6,
whereby serine-1035 was mutated to alanine (A) or aspartic acid (D)
respectively. Empty vector, wild type HDAC6, S1035A and S1035D mutants
were transiently transfected into 293T cells. Wild type and mutant HDAC6
proteins were immunoprecipitated by anti-Flag M2 agrose beads and subject to
histone deacetylase (HDAC) assay as described in Experimental Procedures. As
shown in Fig. 1A, S1035A and S1035D mimicking mutants of HDAC6 did not
significantly affect HDAC6 enzymatic function towards core histones.
Additionally, wild type HDAC6, S1035A and S1035D mutants were also purified
from Sf9 cells and subjected to HDAC assay. As presented in Fig. 1B, S1035A
and S1035D mimicking mutants did not alter the enzymatic activity towards core
histone as compared with wild type HDAC6. The expression of wild type and
mutants of HDAC6 in 293T or Sf9 cells were approximately equal as evidenced
by Commassie blue staining (Fig. 1). Overall, the above results suggest that
phosphorylation or dephosphorylation of HDAC6 at S1035 does not influence its
deacetylase activity using core histone as a substrate.
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HDAC6 Serine-1035 Mimicking Mutants Display Altered TDAC
Activity Compared with Wild Type HDAC6 both In Vitro and In Vivo
α-Tubulin is a well known cytoplasmic substrate of HDAC6 (5, 6). To
determine whether the phosphorylation status of HDAC6 at its serine-1035 site
would affect HDAC6 deacetylase activity towards α-tubulin we first preformed in
vitro assays. First, wild type HDAC6 and its mutants S1035A and S1035D were
transfected into 293T cells. The proteins were immunoprecipitated by anti-Flag
M2 agarose beads, and subjected to tubulin deacetylase (TDAC) assays using
reconstituted microtubules as substrates, described in the Experimental
Procedures. As shown in Fig. 2A, S1035A mutant showed stronger TDAC
activity than wild type HDAC6 and S1035D mutant (lane 3 vs. lanes 2 and 4).
Trichostatin A (TSA), a pan-HDAC inhibitor, was added to the TDAC reaction to
serve as a negative control (Fig. 2A, lane 5). Similarly, wild type HDAC6, S1035A
and S1035D mutant were purified from Sf9 cells and subjected to TDAC assay.
The Sf9 purified proteins also showed similar results in that the S1035A mutant
exhibit enhanced activity towards tubulin. In summary, our results indicated that
HDAC6 S1035 dephosphorylation stimulates HDAC6 TDAC activity in vitro. To
further examine the impact of S1035A mutant on tubulin deacetylation in vivo,
HDAC6 wild type or S1035A mutant were transfected into CHO or H1299 cells.
Whole cell lysates were used to perform immunoblotting analyses. As shown in
Fig. 2B. S1035A transfected cells possess higher levels of acetylated tubulin,
suggesting that it harbors lower TDAC activity compared with wild type.
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Mutation of HDAC6 at Serine-1035 does not Affect HDAC6
Deacetylase Activity towards Cortactin
The F-actin binding protein cortactin is one of HDAC6 cytoplamic
substrate (9). To determine whether HDAC6 and its mutants S1035A and
S1035D deacetylates cortactin in vivo, we used HDAC6 null mouse embryonic
fibroblast (MEFs), stably expressing HDAC6 and the mutants to perform western
blotting analyses. As shown in Fig. 3A, there were no differences between
HDAC6 and HDAC6 mutants in deacetylating cortactin. To further confirm these
results, we co-transfected 293T cells with HDAC6 or mutants, HA-cortactin, and
HA-p300, which is the histone acetyltranferase (HAT) for cortactin. Western
blotting analyses confirmed that mutation of HDAC6 at S1035 does not affect its
ability to deacetylate cortactin, because both mutants effectively deacetylated
cortactin to a similar extent like HDAC6 wild type (Fig. 3B).

HDAC6 Wild Type and S1035D Display Enhanced Deacetylase
Activity Towards β-Catenin
β-catenin is a key effector molecule that functions in the canonical wnt
pathway (13). β-catenin was also determined to be a substrate for HDAC6 (12).
In addition, EGF stimulation of cells enhances HDAC6 ability to deacetylate βcatenin (12). Since we determined that EGF stimulates HDAC6 phosphorylation
through activation of the ERK-MAPK pathway, we wonder whether HDAC6 or its
S1035 mutants would display deacetylase activity towards β-catenin. Since we
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were having difficulty observing acetylated levels of β-catenin in 293T cells (Fig.
4A), we transfected cells with two different HATs of β-catenin, p300 and creb
binding protein (CBP). Cells transfected with p300 showed both HDAC6 and the
phosphorylating mimicking mutants S1035D enhances deacetylation of βcatenin, compared to the S1035A mutants. Interestingly, in the presence of CBP,
both S1035A and S1035D exhibit diminished deacetylase activity towards βcatenin compared to HDAC6 wild type (Fig. 4B). To confirm these data we
performed immunoprecipitation experiments using p300 in both 293T cells and
H1299 lung cancer cells. As shown in Figure 4C and D, both HDAC6 wild type
and S1035D mutant enhances deacetylation of β-catenin.

HDAC6 Wild Type and Serine-1035D Mutant Deacetylate β-Catenin in
the Membrane Compartment
Previous studies indicated that EGF stimulates HDAC6 localization to the
cell membrane, where it interacts with and deacetylate β-catenin (12). Therefore,
we next try to determine whether HDAC6 and the mutants are found at the cell
membrane to promote deacetylation of β-catenin. We transfected H1299 cells
with HDAC6 wild type, S1035A or S1035D mutants, then performed fractionation
studies. As shown in Fig. 5, β-catenin protein is found in both the membrane and
nuclear factions, but was relatively low in the cytoplasmic fraction. Interestingly,
HDAC6 and its phosphorylation mimetic S1035D enhances deacetylation of βcatenin at the membrane compared to the S1035A mutant. However, in the
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nucleus only HDAC6 wild type enhances deacetylation of β-catenin. As shown by
the western blotting analyses, HDAC6 and the mutants are expressed to similar
amounts in each compartment.
We asked whether binding of HDAC6 or its mutants to β-catenin might
affect effective deacetylation of this substrate. We used overexpressed β-catenin,
and HDAC6 wild type or HDAC6 mutants to perform co-immunoprecipitation
experiment. As shown in Fig. 6A, β-catenin co-precipitated with HDAC6 wild type
as well as the mutants to similar extent, but not the vector control. This indicated
that mutation of HDAC6 at the S1035 site does not affect binding of HDAC6 to βcatenin, but affect effective deacetylation of this substrate.
We next used EGF to induce HDAC6 phosphorylation then observe
deacetylation of β-catenin. 293T cells were transfected with HDAC6 wild type or
S1035A mutant then treated with EGF. HDAC6 and mutant protein were
immunoprecipitated then immunoblotted with phospho-serine/thereonine
antibodies to detect phosphorylation of HDAC6. As shown in Fig. 6B (lane 2 vs 4
and lane 3 vs 5) EGF-induced phosphorylation of HDAC6 but not its S1035A
mutants. Phospho-ERK1/2 expression indicated up-regulation of the ERK-MAPK
pathway. Interestingly, HDAC6 in the presence of EGF enhances deacetylation
of β-catenin (Fig. 6B lane 4 vs 5). Overall these data indicated that
phosphoryated HDAC6 at S1035 enhances deacetylation of β-catenin.
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Discussion
Even though HDAC6 is mainly cytoplasmic, it can shuttle between the
cytoplasm and the nucleus, based on specific signals (4). In addition a fraction of
HDAC6 is found in the nucleus during cases of cell cycle arrest (4). Histones
were the first identified substrates of HDACs (16), and HDAC6 can deacetylate
histones in vitro (17, 18). In this study we present that ERK-mediated
phosphorylation of HDAC6 at S1035 within HDAC6 C-terminal affects HDAC6
deacetylase function. While the use of phosphorylation and unphosphorylation
mimicking mutants do not affect HDAC6 ability to deacetylation the core
histones, the cytoplasmic substrates of HDAC6 are differentially deacetylated.
HDAC6 can be phosphorylated by other kinases including EGFR kinase,
Aurora A, and GSK-3β (19-21). In all cases, HDAC6’s ability to deacetylase its
well known cytoplasmic substrate α-tubulin, was affected. For instance, EGFR
phosphorylates HDAC6 at tyrosine-570 and decreases TDAC activity of HDAC6
(19). Since we determined that EGFR-Ras-Raf-MEK-ERK signaling activation
leads to phosphorylation of HDAC6 at a different site, we wonder how this
modification may affect TDAC activity of HDAC6. In vivo we observed decreased
TDAC activity by both the S1035A and S1035D mimicking mutants of HDAC6
(Fig. 2B) and data not shown. It would be interesting to determine how HDAC6
serine-1035 and tyrosine-570 sites in combination affects α-tubulin acetylation
and cell migration. It is intriguing that the enzymatic activity of the S1035A mutant
towards tubulin differs in vitro and in vivo (Fig. 2A and B). One possibility is that
the cell line used for isolation of HDAC6 complex for in vitro TDAC assay (293T)
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and the cell lines used for in vivo TDAC assay (CHO and H1299) were different.
Another possibility is that ERK1/2 was present in the in vivo but not in vitro TDAC
assays. ERK1/2 is associated with and phosphorylates microtubules (22) which
may account for the different results of the in vitro and in vivo TDAC assays.
Cortactin is an F-actin binding protein that plays an essential role in cell
migration (9-11) and angiogenesis (11). Cortactin is also an HDAC6 substrate
(9). In our experiments we did not observe any differences in HDAC6 and its
mutants in the deacetylation of cortactin (Fig. 3). This observation is consistent
with the fact that ERK1/2 is associated with the microtubules but not with actin or
intermediate filaments (22).
β-catenin is an effector molecule of the canonical Wnt pathway (13). βcatenin is regulated by phosphorylation, which targets it for degradation by the
destruction complex (13). β-catenin is also among the emerging list of HDAC6
substrates (12). It was previous shown that HDAC6 deacetylation of β-catenin at
lysine-49 is induced by EGF. This stabilizes β-catenin, allowing it to translocate
to the nucleus where it activates target genes such as c-Myc (12). We used
S1035A and S1035D mutants of HDAC6 and observed enhanced deacetylation
of β-catenin in the presence of S1035D mutant, similar to that of HDAC6 wild
type. We also observed that this deacetylation is enhanced at the cell membrane
(Fig. 5). This is in agreement with other reports that EGF induces HDAC6
deacetylation of β-catenin at the cell membrane (12). Mutation in the Wnt/βcatenin pathway are implicated in several disease process including bone
disease, and cancer especially in tissues that is dependent on Wnt signaling for
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renewal or repair (23). β-catenin lysine-49, which is the target of HDAC6
deacetylase activity, is a conserved site from drosophila to human (24). In
patients with thyroid carcinomas lysine-49 is mutated to arginine (12).
Interestingly, the convergences of Wnt-β-catenin with EGFR signaling has been
observed in many different cancer processes including cancer of the lung, breast
and colon (25). Our data showed a difference in the HATs, p300 and CBP in
affecting deacetylation of β-catenin. Both p300 and CBP improves β-catenin
stability through inhibition of ubiquitin dependent degradation, thus allowing βcatenin translocation to the nucleus to enhance its transcriptional activity (26).
The HAT p300, can also acetylate HDAC6 to regulate its TDAC activity and
nuclear import (27). It is also possible that cross talk between p300 and HDAC6
enhances HDAC6 activity towards β-catenin as seen in our results.
It is well documented that HDAC6 supports a role in tumorigenesis (28). In
addition, HDAC6 deacetylation of its cytoplasmic substrates promotes processes
involved in promoting cancers, such as cell migration, metastasis and
angiogenesis. Here we show that ERK-mediated phosphorylation of HDAC6
affects deacetylation of its substrates that are also involved in these processes.
β-catenin in particular is a major therapeutic target, because of the role it plays in
promoting tumorigenesis. Several inhibitors to interrupt various stages of the
Wnt/β-catenin pathway has remain mainly unsuccessful (23). Because of the
convergence of ERK-MAPK pathway, HDAC6, and Wnt/β-catenin signaling, it is
possible that combination inhibitors may be effective in some tumors that are
promoted by β-catenin up-regulation.
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Experimental Procedures
Plasmids, Antibodies, Reagents, and Cell lines
HA-HD6-F is described in (9). The point mutations on this construct were
created by QuikChange® XL Site-Directed Mutagenesis Kit (Stratagene). For
HA-HD6(S1035A)-F, the primers used are :
5’ CCACCAGACCCCCCCAACCGCACCTGTGCAG 3’ and,
5’ CTGCACAGGTGCGGTTGGGGGGGTCTGGTGG 3’.
For HA-HD6(S1035D)-F, the primers used are
5’ CCACCAGACCCCCCCAACCGACCCTGTGCAG 3’ and
5’ CTGCACAGGGTCGGTTGGGGGGGTCTGGTGG 3’. The PCR cycle was as
follows: 95°C, 1 min; followed by 95°C, 50 sec; 60°C , 50 sec; 68°C, 20 min for
25 cycles and then 68°C, 30 min.
Anti-HDAC6 (H300) , HSP60, and Total β-catenin antibodies were
purchased from Santa Cruz Biotechnology. Anti-HA antibody was purchased
from Covance. Anti-acetylated α-tubulin antibody, anti-β-tubulin antibody and
lipofectamine 2000 reagent were purchased from Invitrogen. Anti-Flag antibody
purchased from Sigma. Microtubules (#MT001-A) were purchased from
Cytoskeleton; Anti-ERK1/2 antibody (#9102), anti-phospho-ERK1/2
(Thr202/Tyr204) antibody (#9101), Parp, EGF, and acetyl-β-catenin (lys49), were
purchased from Cell Signaling Inc.
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CHO, a Chinese hamster ovary cell line, H1299, HDAC6 wild type and
knockout MEFs, and 293T cells were cultured in DMEM medium with penicillin
(100 U/ml), streptomycin (100 mg/ml) and 10% fetal bovine serum (FBS) and
incubated at 37ºC with 5% CO2.

Establishment of Stable Clones
To generate the rescue clones in HD6 knockout MEFs, empty vector, HAHD6-F, HA-HD6(S1035A)-F and HA-HD6(S1035D)-F were transfected into HD6
knockout MEFs using Lipofectamine Plus reagents. One day after transfection,
500 µg/ml G418 was added to the medium to select positive cells. Ten days later,
stable cell lines were subcloned to 60 mm dishes and 300 µg/ml G418 was
added to maintain the stable clones.

Generation of Baculoviruses
The baculoviruses expressing HA-HD6-F, HA-HD6(S1035A)-F and HAHD6(S1035D)-F were generated from modified pFastBac-HTb donor vector
(Invitrogen) in which His tag was changed to Flag tag. The bacmids containing
the above cDNAs were generated by transposition in E.coli cells according to the
manual of Bac-to-Bac system (Invitrogene). Baculoviruses expressing wild type
and A or D mutant of HDAC6 proteins were generated by transfection of
recombinant bacmids into Sf9 cells using CellfectinRII Reagent (Invitrogen). The
P2 stocks of baculovirus were used to infect Sf9 cells. The overexpressed HA-
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HD6-F, HA-HD6(S1035A)-F and HA-HD6(S1035D)-F in Sf9 cells were purified
using anti-Flag M2 agarose (Sigma).

Immunoprecipitation and Immunoblotting
For immunoprecipitations, cells were lysed in LS buffer (PBS [pH 7.5],
10% glycerol, 0.1% NP-40, and protease inhibitor cocktail). Lysates were
incubated with protein A or protein G agarose for 2 hours for pre-clearing prior to
incubation with the indicated primary antibodies for 12 h at 4°C.
Immunocomplexes were collected, washed four times in lysis buffer, and
resolved by SDS-PAGE. For immunoblotting, samples were transferred to
nitrocellulose membranes that were then probed with the indicated antibodies.
Bound antibodies were detected using a Chemiluminescent Detection Kit
(Pierce).

Histone Deacetylase (HDAC) Assay
F-vector, HA-HD6-F, HA-HD6(S1035A)-F or HA-HD6(S1035D)-F proteins
purified from 293T transfected cells lysate were precleared with protein A beads
and immunoprecipitated with anti- Flag beads before protein deacetylase activity
was determined. Briefly, [3H]acetate-incorporated histones were isolated from
butyrate-treated HeLa cells by acid extraction as described in (27). Purified core
histones (12,000 cpm) were incubated with immunoprecipitates in 150 μl of icecold histone deacetylase buffer (20 mM Tris [pH 8.0], 150 mM NaCl, and 10%
glycerol) at 37°C for 2 hr. The reaction was terminated by the addition of an
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equal volume of stop solution (0.16 M acetic acid, 1.0 M HCl) and mixed well by
vortexing. The released [3H]acetate was extracted with ethyl acetate and
combined with scintillation mixture for analysis. Additionally, HD6 and its mutants
(S1035A and S1035D) were also obtained from Sf9 insect cells. The purified
proteins were used to performed HDAC assay as was done with 293T cells.

Tubulin Deacetylase (TDAC) Assay
First, 293T cells were transfected with empty vector, HA-HD6-F, HAHD6(S1035A)-F or HA-HD6(S1035D)-F plasmid. After 48 hrs, cells were
collected and lysed with lysis buffer (PBS [pH 7.5], 10% glycerol, 0.1% NP-40,
PMSF and protease inhibitor cocktail), pre-cleared with protein A beads then
immunoprecipitated with anti-Flag beads over night at 4°C. Following incubation,
beads were washed 3X with lysis buffer containing protease inhibitor. TDAC
assay was carried out as described (11). Briefly, proteins were eluted with 200
µg/ml Flag peptide and incubated with 100 µl of 2X TDAC buffer (20 mM Tris-Cl
pH 8.0, 20 mM NaCl) and 50 µg reconstituted microtubules (Cytoskeleton) in a
200 µL reaction at 37°C for 2 hrs, then transferred to ice for 15 mins. A fraction of
the reactions were analyzed by Coomassie blue staining or Western blot analysis
using anti-α-tubulin and anti-acetylated α-tubulin antibodies. Additionally, wild
type and mutants of HD6 were also isolated from Sf9 cells and were used to
perform the TDAC assay.
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Cell Fractionation
H1299 cells were transfected with HDAC6 WT or the S1035 mutants.
Following transfection, cells were collected and cytoplasmic, membrane and
nuclear fractionation was performed using a fractionation kit purchased from
Millipore (Cat #2145RF). Collected fraction lysates were then subjected to
immunoblotting.

Statistics
Each experiment were performed at least three times. Statistical analysis
was performed using the student’s t-test. p-value < 0.05 was considered
significant.
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FIGURES

Figure.3.1. Substitution of Serine-1035 to A or D does not affect HDAC6
Enzymatic Activity Towards Core Histones. (A) 293T cells were transiently
transfected with the indicated plasmids as indicated. HDAC6 wild type or mutant
complexes were immunoprecipitated by anti-Flag M2 agarose beads, then
subjected to the HDAC assay as described in the Experimental Procedures. The
purified HDAC6 wild type or mutant complexes used in the HDAC assays were
also shown by Coomassie blue staining. (B) Sf9 cells were transduced by the
indicated viruses. HDAC6 wild type or mutant proteins were purified by anti-Flag
M2 agarose and then subjected to the HDAC assays as (A). The purified HDAC6
wild type or mutant proteins used in the HDAC assays were also shown by
Coomassie blue staining. Data shown are representative of at least three
repeated experiments. NS stands for not significant.
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A

B

Figure.3.2. Serine-1035 HDAC6 Mutants Display Altered TDAC Activity
Compared with the wild Type In Vitro and In Vivo (A)293T cells were
transiently transfected with the indicated plasmids as indicated. HDAC6 wild type
or mutant complexes were immunoprecipitated by anti-Flag M2 agarose beads,
then subjected to the TDAC assay as described in the Experimental section. The
purified HDAC6 wild type or mutant complexes used in the TDAC assays were
also shown by Coomassie blue staining. Sf9 cells were transduced by the
indicated viruses. HDAC6 wild type or mutant proteins were purified by anti-Flag
M2 agarose and then subjected to TDAC assays as before. The purified HDAC6
wild type or mutant proteins used in the TDAC assays were also shown by
Coomassie blue staining. (B) CHO and H1299 cells were transfected with the
indicated plasmids. After thirty six hours, cells were harvested and lysed. Anti-Actubulin and anti-HA Western blotting analyses were performed.
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Figure.3.3. HDAC6 Wild Type, HDAC6(S1035A), and HDAC6(S1035D) Exhibit
Similar Ability to Deacetylate Cortactin in MEFs or 293T Cells. (A) Western
blotting analyses were performed using HDAC6KO MEFs stably expressing
empty vector, HA-HD6-F, HA-HD6(S1035A)-F or HA-HD6(S1035D)-F with
indicated antibodies. (B) 293T cells were transfected with indicated plasmids.
The Western blotting analyses were carried out with indicated antibodies.
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Figure.3.4. HDAC6 Wild Type and HDAC6(S1035D) Phosphorylation
Mimicking Mutants Enhances Deacetylation of β-Catenin. (A, B) 293T cells
were transfected with indicated plasmids. The Western blotting analyses were
carried out using indicated antibodies. (C) H1299 cells (D) 293T cells were
transiently transfected with the plasmids as indicated. HDAC6 wild type or mutant
complexes were immunoprecipitated by anti-HA beads, followed by western
blotting analysis using the ac-β-catenin(lys49) antibodies. The same blots were
then stripped and reprobed with anti-HA antibodies.
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Figure.3.5. HDAC6 Wild Type and HDAC6(S1035D) Phosphorylation
Mimicking Mutants Enhances Deacetylation of β-Catenin at the Cell
Membrane. H1299 cells were transiently transfected with the plasmids as
indicated. 36 hrs following transfection, cells were collected and subjected to
fractionation using a fractionation kit (Millipore) following the manufacture’s
protocol. A direct western blot analysis was performed using the indicated
antibodies. EGFR, HSP60 and PARP antibodies were used as membrane,
cytoplasmic and nuclear fractions markers respectively.
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Figure.3.6. HDAC6 Binds to β-Catenin and Enhances its Deacetylation
during EGF Stimulation. (A) 293T cells were transfected with indicated
plasmids. HDAC6 wild type or mutant complexes were immunoprecipitated by
anti-Flag beads, followed by western blotting analysis with the indicated
antibodies. The same blots were then stripped and reprobed with anti-HA
antibodies. (B) 293 T cells were transfected with the indicated plasmids. 36 hrs
following transfection, cells were stimulated with 50 ng/mL EGF for 2 mins.
HDAC6 wild type or mutant complexes were immunoprecipitated by anti-HA
beads, followed by western blotting analysis using the indicated antibodies. A
direct western blotting analysis were carried out to determine the expression of
ac-β-catenin(lys49), total β-catenin, p-ERK1/2, T-ERK1/2, and β-tubulin.
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CHAPTER FOUR
HDAC6 REGULATES CELL MIGRATION
BOTH IN VITRO AND IN VIVO

Abstract
The predominantly cytoplasmic histone deacetylase 6 (HDAC6) is
involved in promoting cell proliferation, cell migration, metastasis and
angiogenesis, which are all hallmarks of cancer. HDAC6 is overexpressed in
several cancer models and is required for efficient oncogenic transformation and
tumor formation. In this study we report that activation of the ERK-MAPK
pathway promotes cell migration in mouse embryonic fibroblasts (MEFs) cells in
an HDAC6-dependent manner. An unphosphorylation mimicking mutant of
HDAC6’s serine-1035 site significantly reduced the migration potential of MEFs
compared with HDAC6 wild type or the phosphorylation mimicking mutant. Our
data suggest that HDAC6 promotes cell migration through two of its cytoplasmic
substrates, α-tubulin and β-catenin. In addition, for the first time we reported
evidence to support the hypothesis that HDAC6 promotes in vivo cell migration in
a mouse model. Given that both HDAC6 and the ERK-MAPK pathway are of
interest in drug inhibitors studies, targeting both maybe beneficial for future
studies.
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factor beta.

Introduction
Acetylation and deacetylation are reversible processes that are catalyzed
by histone acetyltransferase (HATs) and histone deacetylases (HDACs),
respectively (1). In addition to modifying histones, HATs and HDACs are involved
in modifying numerous non-histone proteins that are important in regulating
cellular processes in both eukaryotic and prokaryotic systems (1-3). These nonhistone proteins function in DNA repair, transcription, replication, apoptosis, and
signaling (4). In addition, many of these proteins are chaperones, metabolic
enzymes, cytoskeletal proteins or viral proteins (4). In particular, HDACs are
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involved in regulating the hallmarks of cancer, which includes, apoptosis,
angiogenesis, proliferation, cell cycle progression, migration, metastasis, and cell
differentiation (5). As a result, numerous research efforts are aimed at using
histone deacetylase inhibitors (HDACi) alone, or in combination with other drugs
for treatment of various cancers as well as neurodegenerative disorders (6, 7).
However, because HDACs regulate diverse cellular functions, additional
research is needed to identify how specific HDACs promote their functions, as
well as better understand how HDACi achieve their anti-tumor effect.
The predominantly localized cytoplasmic deacetylase, HDAC6, is one of
the HDACs that are known to regulate some of the hallmarks of cancer (8-11).
HDAC6 regulates multiple cytoplasmic processes through the deacetylation of its
cytoplasmic substrates α-tubulin, cortactin, heat shock protein 90 (HSP90) and βcatenin (9, 10, 12, 13). The first cytoplasmic substrate of HDAC6 shown to
regulate cell migration was α-tubulin (9). It was shown that overexpression of
HDAC6 promotes chemotactic cell movement and that HDAC6-mediated
deacetylation of microtubules promotes cell motility (9). HDAC6 deacetylation of
α-tubulin is also required to promote invasive cell motility, and increase total focal
adhesion area (14). Acetylation and deacetylation of tubulin affects microtubules
dynamic (15). Additionally, HDAC6 deacetylates α-tubulin and promotes
microtubule disassembly (15). Tran et al., showed that inhibition of HDAC6 in
cells, results in decreased microtubule dynamic leading to increased focal
adhesion accumulation and decreased in fibroblast motility (14). HDAC6 is also
required for invadopodia formation and function through possible deacetylation of
110

its cytoplasmic substrates α-tubulin and cortactin, and is required for breast
cancer cell invasion (16).
β-catenin, another cytoplasmic substrate of HDAC6, is the central
molecule of the canonical Wnt pathway (13). β-catenin is usually found at the cell
membrane tethered to E-caderin. This β-catenin and E-cadherin interaction is
regulated by phosphorylation (17). β-catenin promotes epithelial cell migration,
and its stabilized form supports tumor formation in the mouse xenograft model
(18). In addition, c-Myc, a nuclear target of β-catenin, plays a significant role in
various disease states including cancer (19, 20). Inhibiting HDAC6 deacetylation
of β-catenin, prevents β-catenin nuclear localization and consequently decreases
activation of c-Myc expression (13). HDAC6 was shown to associate with βcatenin through a complex with glycoprotein CD133 (21). Down-regulation of
HDAC6, as well as CD133 leads to increased acetylation of β-catenin and its
degradation, which correlates with decreased in vitro proliferation, colony
formation, invasion, and decrease in tumor xenograft growth in vivo (21).
HDAC6 also plays a role in tumorigenesis (22). HDAC6 expression is
induced upon oncogenic Ras, and HDAC6 is required for efficient oncogenic
transformation and tumor formation (22). Inactivating HDAC6 decreases
anchorage independent growth in several cell lines and also reduces tumor
formation in mice (22). HDAC6 decreases ciliary expression, and targeting
HDAC6 in cholangiocarcinoma cell line model decreases the tumorigenic
phenotype of cell in vitro and in an animal model (23). Epithelial mesenchymal
transition (EMT) is a key event involved in tumor progression (24). HDAC6
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modulates transforming growth factor beta (TGF-β)-induced EMT by
deacetylating α-tubulin in human lung epithelial cells (25). In addition, HDAC6 is
required for growth factor-induced activation of other pathways including the
extracellular signal regulated kinase (ERK) mitogen activated protein kinase
(MAPK) signaling pathway (22). The ERK-MAPK signaling pathway has a pivotal
role in tumor promotion because of the activating mutations found upstream in
the pathway (26). The downstream kinases ERK1 and ERK2 phosphorylate
countless substrates both in the cytoplasm and the nucleus (27). In fact,
downstream substrates of ERK1/2 found both in the cytoplasm and nucleus were
shown to promote cell migration (28-30).
In this study, we showed that ERK-mediated phosphorylation of HDAC6, a
novel substrate of ERK1, promotes cell migration in mouse embryonic fibroblasts
cells through deacetylation of its cytoplasmic substrates α-tubulin and β-catenin.
In addition, HDAC6 also promotes cell migration in vitro in a lung cancer cell line
model and in vivo using tail vein migration model.

Results
Active C-Raf-Mediated Cell Migration is via HDAC6
Cell migration in fibroblast cells lines such as NIH 3T3 cells have
previously been used to study 2D model cell migration, and results have
indicated that HDAC6 promotes chemotactic cell movement (9). After we
identified HDAC6 as a novel substrate of ERK1, we wonder whether the ERK112

MAPK signaling cascade influenced cell migration via HDAC6. ERK1/2 was
previously shown to promote cell migration by phosphorylating one of its
cytoplasmic substrates myosin light chain kinase (MLCK) to promote cell
migration (31). We therefore overexpressed active cRaf (cRaf-BxB) in wild type
or HDAC6 null MEFs and performed migration studies. We employed a transwell
migration filter whereby serum starved cells were seeded on the top of a
membrane coated with collagen and allowed to migrate to a lower compartment
attracted by serum. As shown in Fig.1A, active cRaf significantly increased cell
migration in wild type MEFs compared with HDAC6 null MEFs in the migration
assay. Indeed, active cRaf leads to elevated phospho-ERK1/2 levels in both wild
type and HDAC6 null MEFs Fig. 1C. (lanes 3 and 4), indicating activation of the
ERK-MAPK pathway. Interestingly, HDAC6 null MEFs possessed higher
phospho-ERK1/2 levels compared with wild type (lane 2 vs. lane1). This
observation raised the possibility that HDAC6 plays a role in suppressing ERK1/2
activity. Further examination will be warranted.

Unphosphorylation of HDAC6 at Serine-1035 Exerts Lower Migration
Potential Compared with Wild Type HDAC6
Since we observed a difference in migration potential in HDAC6 wild type
cells due to activation of the ERK-MAPK pathway (Fig.1), we next used HDAC6
null MEFs stably expressing an unphosphorylation or phosphorylation S1035
mimicking mutant of HDAC6 and performed migration studies. As shown in Fig.
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2A and B, S1035A-rescued clone in HDAC6 null MEFs displayed lower migration
potential compared with HDAC6 wild type and S1035D mutant. Protein
expression in those rescued clones was approximately equal (Fig.6C).
Interestingly, we observed that the unphosphorylated form of HDAC6 also
inhibits deacetylaion of α-tubulin in vivo. Others have shown that use of an
HDAC6 specific inhibitor as well as, a catalytically inactive HDAC6 mutant
showed that inhibiting deacetylation of α-tubulin results in retarded cell motility (9,
32). Our results indicate that dephosphorylation of HDAC6 decreased its ability to
induce cell migration, and agreed with others that deacetylaion of α-tubulin plays
a role in promoting cell migration.

β-Catenin is Involved in HDAC6-Mediated Cell Migration
Since the phosphorylation mimicking mutant of HDAC6 showed enhanced
cell migration compared to the unphosphorylation mutant, we wonder whether
ERK1-mediated phosphorylation of HDAC6 could promote cell migration via
another one of HDAC6 cytoplasmic substrate. β-catenin was previously shown to
promote cell migration (18). Interestingly, epidermal growth factor (EGF)
treatment enhances HDAC6 ability to deacetylate β-catenin (13). And in a
separate study, EGF treatment enhanced cell migration in a β-catenin dependent
manner (18). As such, we hypothesized that β-catenin is a possible target of
phosphorylated HDAC6 and can promote cell migration via the EGF-activated
ERK-MAPK pathway. We therefore used HDAC6 wild type MEFs cells to
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transiently knock down β-catenin protein using siRNA technique, then performed
migration studies. Our data illustrated that β-catenin knock down significantly
decreases cell migration in comparison to the control siRNA group (Fig. 3A and
B).suggesting that β-catenin is indeed involved in cell migration.

HDAC6 Promotes Human Lung Cancer Cell Migration In Vitro and In
Vivo
Previous studies indicated that HDAC6 promotes tumorigenesis (21, 22,
33). Several studies have also indicated HDAC6’s role in promoting cell migration
using different cell line models (9, 10, 32). However, in vivo migration models
have not been shown. We wondered whether HDAC6 would promote cell
migration in a mouse model. We used two different human lung cancer cell lines
for this study. First, H292, a pulmonary carcinoma cell line derived from lymph
node metastasis; and A549, an epithelial lung carcinoma cell line. In addition, the
A549 cells expressed the luciferase genes. Both cell lines were stably depleted
of HDAC6. Western blotting analyses indicated down regulation of HDAC6
compared to the control group, (Fig. 4A and 5A). We then performed migration
and invasion studies using the transwell migration technique. For migration
studies, collagen I was used to coat the transwell chambers, while matrigel was
used to coat the transwell chambers for invasion studies. We observed that in
H292 cells, there was a significant difference in HDAC6 ability to promote both
cell migration and invasion compared to the HDAC6 knock down cells (Fig. 4B,
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C). Similar data was also observed in a wound healing assay for cell migration
(data not shown). Interestingly, in the A549 cells, we did not observe a significant
difference in HDAC6’s ability to promote cell migration and invasion using a
transwell migration model or wound healing migration model (data not shown).
We next wanted to determine whether HDAC6 would promote cell
migration and metastasis in vivo, therefore, we used athymic nude mice to
perform tail vein injections and allowed cells to migrate for a six week period.
Because H292 cells were not luciferase tagged, we weighed the mice weekly to
observe any differences in weight between the HDAC6 wild type and HDAC6
knock down groups. At the end of the six weeks period we removed the lungs
and performed a macroscopic analysis of the lungs and surrounding organs for
the presence of nodules. We did not observe any significant difference in weight
between the HDAC6 wild type and knock down groups (Fig. 4D). But we
observed in the HDAC6 wild type group the presence of numerous nodules on
the surface of the lungs, as compared to the HDAC6 knock down group (Fig. 4E
and F). However, the difference was not significant owing to the smaller sample
size.
Because the A549 cells were luciferase tagged we injected the mice
weekly with the luciferase substrate luciferin, and observed growth of the cells
using ex vivo imaging. As illustrated in Fig. 5B, cells were present in the lungs of
the mice on the day of cell injection via the tail vein (Day 0), indicating a
successful injection. At the end of the six weeks period we also performed a
macroscopic analysis of the lungs and surrounding organs for the presence of
116

nodules. Similar to the H292 group, we did not observed any differences in the
HDAC6 wild type and knock down groups in terms of mice weight (Fig. 5C).
However, we observed a significant difference in the number of nodule present
on the surface of the lungs in the HDAC6 wild type group compared to HDAC6
knock down group (Fig. 5D and E).
For both the H292 and A549 groups we did not observe any nodules on
other surrounding organs or tissues other than the lungs. Overall, our results
supports that HDAC6 can also promote cell migration of human cancer cell lines
in vitro and in vivo using a mouse model.

HDAC6 Protein Expression is Up-Regulated in a Panel of Lung
Cancer Cell Lines Compared to Normal Lung Cells
Others reported that HDAC6 mRNA and protein levels are up-regulated in
cancer cells and tissues compared to the normal (34-36), as such, we performed
western blotting analyses on a panel of normal lung and lung cancer cell lines.
LL24 and HBE4 are from normal fibroblasts and epithelial cells, respectively. As
presented in Fig. 6, we observed that HDAC6 protein is mainly up-regulated in
the other cell lines compared to LL24 and HBE4. Interestingly, cell lines from
H2122 to H292 were derived from a metastatic site, and we observed that
HDAC6 expression was much lower in these cell lines. Further studies are
needed to determine whether this trend have any significance. In addition,
acetylated β-catenin levels are decreased in the cell lines derived from metastatic
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sites. This may be a reflection of β-catenin involvement in promoting cell
migration and tumor formation (18, 37). EGFR and phospho-ERK1/2 protein
expression is also up-regulated in the majority of these cells lines. This is not
surprising because numerous studies have implicated that both EGFR and
ERK1/2 as major players in tumorigenesis (26).

Discussion
In this study we presented evidence to support the hypothesis that
phosphorylation of HDAC6 via activation of the ERK-MAPK pathway promotes
cell migration in MEFs. We showed that an unphosphorylation mimetic of HDAC6
serine-1035 site reduces migration possibly due to diminished deacetylation of its
cytoplasmic substrates α-tubulin. We also showed that HDAC6 may also promote
cell migration via deacetylation of β-catenin. Finally, we demonstrated that
HDAC6 promotes cell migration of human cancer cells in vivo.
Activated ERK-MAPK pathway is involved in promoting cell migration via
phosphorylation of downstream targets in both the nucleus and cytoplasm (30,
31). In the cytoplasm, ERK1/2 phosphorylates MLCK which then phosphorylates
myosin light chain (MLC) leading to cytoskeleton contraction involved in cell
movement, independent of ERK1/2 entry into the nucleus (31). After we identified
HDAC6 as a novel target of ERK1, we asked whether phosphorylation of HDAC6
would affect HDAC6-mediated cell migration. As shown in Fig.1, activation of the
ERK-MAPK pathway induced cell migration in an HDAC6 dependent manner.
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Western blotting analyses also indicated activation of the ERK-MAPK pathway.
These results demonstrated that ERK-MAPK signaling plays a critical role in
promoting cell migration via HDAC6. It was previously shown that mutationally
active MAPK ERK kinase (MEK) dramatically increased cell migration by four to
five folds relative to control cells when Cos-7 cells were used in the experiment
(31), however, we did not observed a significant effect using active MEK in MEFs
cells.
Previous studies have indicated that HDAC6-mediated deacetylation of αtubulin promotes cell motility (9, 32). We next used a phosphorylation and
unphosphorylation mimicking mutant of HDAC6 to perform cell migration studies.
We observed that unphoshorylation of HDAC6 at the ERK1 phosphorylation site
significantly decreased migration of cell (Fig. 2). In addition, we observed that
unphoshorylation of HDAC6 also inhibited deacetylation of α-tubulin in vivo,
which may explain the inhibited cell migration observed in our studies. Our
results is also in agreement with other studies that indicated that inhibition of
HDACs using the pan HDACi trichostatin A and the HDAC6 specific inhibitor
tubacin leads to hyperacetylated tubulin, resulting in decreased cell motility (14,
32).
In our in vivo and in vitro deacetylation experiments, we did not observed
deacetylation of α-tubulin by the phosphorylation mimicking HDAC6 mutant.
However, our migration studies indicated that phosphorylation of HDAC6 also
promotes cell migrations (Fig. 2). We therefore wondered whether additional
HDAC6 substrates were involved in promoting cell migration. It was previously
119

demonstrated that EGF stimulates HDAC6 dependent deacetylation of β-catenin
at lysine-49, promoting β-catenin nuclear accumulation and activation of βcatenin target genes (13). In addition, both hepatocyte growth factor (HGF) and
EGF induced β-catenin signaling stimulate cell motility. The stabilized form of βcatenin also showed enhanced migration and the addition of HGF and EGF
further enhanced migration (18). In a separate study, it was reported that HDAC6
forms a complex with the cell marker CD133, allowing HDAC6 to deacetylate and
stabilize β-catenin (21). Furthermore, HDAC6 knock down leads to decreased
cell proliferation, colony formation, invasion in cell lines, and decreased tumor
growth in the xenograft model (21). We therefore knocked down β-catenin
expression using siRNA techniques, and performed migration studies. Our
results indicated that β-catenin is important in promoting cell migration in HDAC6
wild type MEFs (Fig. 3). It is possible that HDAC6 deacetylates β-catenin, and
promote β-catenin activation of its target genes to promote cell migration. One
well known nuclear target of β-catenin is c-Myc (13, 19), which is involved in
promoting tumorigenesis (20). We believe that EGF can promote phosphorylation
of HDAC6, which enhances deacetylation and stabilization of β-catenin to
promote migration.
HDAC6 has long been implicated in promoting tumorigenesis (22, 23).
HDAC6 protein is over expressed in several cancer models and cell lines
including oral squamous cell carcinoma cell lines, human primary tumor, and in
human breast cancer tissues (34-36). Our lab has also observed elevated levels
of HDAC6 protein in human ovarian cancer tissues compared to benign
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counterparts, and elevated levels of HDAC6 protein in ovarian cancer cell lines
compared to normal ovarian cell lines (unpublished data). As shown in Fig. 6, a
similar trend of HDAC6 protein up-regulation is observed in a panel of lung
cancer cell lines compared to the normal lung cell lines.
Using H292 lung cancer cell lines, we observed that stable HDAC6
knockdown significantly impaired both cell migration and cell invasion (Fig. 4B
and C). Using A549 lung cancer cells, we did not observe a significant difference
in cell migration or cell invasion between the HDAC6 wild type and HDAC6 knock
down cells as seen for the H292 cell lines. Other studies using A549 cells in cell
migration studies also used EGF to stimulate cell migration (38). Since we did not
used EGF in our study, this could account for why we did not observe a
significant difference in these cell lines. To complement the cell line migration
model, we performed tail vein injection of H292 and A549 cells using nude mice.
We observed the presence of nodules on the lungs, of the mice after six weeks.
Both cell lines used showed the presence of HDAC6 promoted cell migration in
vivo compared to the HDAC6 knock down groups. However, the A549 model
produced a significant difference, whereas, in the H292, group even though a
difference was observed, it was not as significant owing to the small sample size.
It is plausible that activation of the ERK-MAPK pathway promotes in vivo
migration via phosphorylation of HDAC6. It was previously shown that HDAC6deficient cells and mice are more resistant to oncogenic Ras-induced
oncogenesis (22). Our lab previously showed that knock down of HDAC6
significantly reduced tumor volume and tumor weight in a mouse xenograft
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model, indicating that HDAC6 is essential in promoting tumor growth (33). We
also found that reduced tumor growth in HDAC6 knock down cell was due to
increased basal pro apoptotic signaling, rather than decreased proliferation (33).
In addition, in cell survival assay, depletion of HDAC6 significantly decreased
colony formation in H292 cells (33).
Our data as presented supports HDAC6 role in promoting cell migration
through deacetylation of its cytoplasmic substrates α-tubulin and β-catenin. We
also found that phosphorylation of HDAC6 by ERK1 also contributes to HDAC6mediated cell migration. In addition, we found for the first time that HDAC6
promotes in vivo cell migration using two different human lung cancer cell lines.
Several studies are using HDACi in combination with other drugs for treatment of
cancer and other diseased states (6). Our group and others have already shown
that HDAC6 sensitizes cancer cells to anti-cancer agents (33, 39). Using A549
cells, it was shown that cells with reduced HDAC6 expression were more
sensitive to MEK inhibitor, compared to cells expressing HDAC6 (40). In addition,
MEK inhibitors used in combination with HDACi indicated a lower threshold for
HDACi. Therefore, based on our results, we identify HDAC6, as well as, ERK1/2,
as possible targets for future drug designs.
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Experimental Procedures
Plasmids, Antibodies, Reagents, and Cell lines
The hemagglutinin (HA) and flag (F) double tagged HDAC6, HA-HD6-F is
described in (10). The point mutations on this construct were created by
QuikChange® XL Site-Directed Mutagenesis Kit (Stratagene). For HAHD6(S1035A)-F, the primers used are :
5’ CCACCAGACCCCCCCAACCGCACCTGTGCAG 3’ and,
5’ CTGCACAGGTGCGGTTGGGGGGGTCTGGTGG 3’.
For HA-HD6(S1035D)-F, the primers used are
5’ CCACCAGACCCCCCCAACCGACCCTGTGCAG 3’ and
5’ CTGCACAGGGTCGGTTGGGGGGGTCTGGTGG 3’. The PCR cycle was as
follows: 95°C, 1 min; followed by 95°C, 50 sec; 60°C , 50 sec; 68°C, 20 min for
25 cycles and then 68°C, 30 min.
C-RAF-BXB was described in (41). Anti-HDAC6 (H300) and Total βcatenin antibodies were purchased from Santa Cruz Biotechnology. Anti-HA
antibody was purchased from Covance. Anti-acetylated α-tubulin antibody, antiβ-tubulin antibody and lipofectamine 2000 reagent were purchased from
Invitrogen. Anti-Flag antibody and collagen I (#C7661) were purchased from
Sigma. Anti-ERK1/2 antibody (#9102), anti-phospho-ERK1/2 (Thr202/Tyr204)
antibody (#9101), β-catenin and control siRNA were purchased from Cell
Signaling. Luciferin firefly Potassium salt was purchased from Perkin Elmer.
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HDAC6 wild type and knockout MEFs, were cultured in DMEM medium
with penicillin (100 U/ml), streptomycin (100 mg/ml) and 10% fetal bovine serum
(FBS) and incubated at 37ºC with 5% CO2. NSCLC cell lines ADLC, A549,
EPLC, H292, H460, A460, H522, H2122, H661 and H1299 were obtained from
the American Type Culture Collection (ATCC). Cells were cultured in RPMI 1640
medium with penicillin (100 U/ml), streptomycin (100 μg/ml) and 10% fetal bovine
serum (FBS) and incubated at 37°C with 5% CO2.
H292 cells were obtained from ATCC and A549-luciferase cells were
obtained from Moffitt core. Cells were transiently transfected with control vector
pRS (Cat.# TR20003) or shRNA vector against HDAC6 (recognize sequence 5AGGTCTACTGTGGTCGTTACATCAATGGC-3’, tube ID:TI349960, ORIGENE).
Twenty-four hours after transfection, cells were split to duplicate plates of 1:20 in
RPMI 1640 medium containing 0.5 μg/ml puromycin. Puromycin was replenished
every 2 days to maintain sufficient level of selection pressure. The well-isolated
single clones were transferred into 24-well plates. The knockdown effect was
verified by Western Blotting analysis using anti-HDAC6 antibodies.

Establishment of stable clones
To generate the rescue clones in HDAC6 knockout MEFs, empty vector,
HA-HD6-F, HA-HD6(S1035A)-F and HA-HD6(S1035D)-F were transfected into
HD6 knockout MEFs using Lipofectamine Plus reagents. One day after
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transfection, 500 µg/ml G418 was added to the medium to select positive cells.
Ten days later, stable cell lines were subcloned to 60 mm dishes and 300 µg/ml
G418 was added to maintain the stable clones. The generated stable clones
were used in migration experiments.
Immunoblotting Analysis
Cells were lysed in LS buffer (PBS [pH 7.5], 10% glycerol, 0.1% NP-40,
and protease inhibitor cocktail). Protein concentration of all samples was
determined by Bradford reagent (Bio-Rad). Proteins were resolved on 8% SDSPAGE gels and transferred to nitrocellulose membranes. The membranes were
probed with primary antibodies and horseradish peroxidase (HRP) conjugated
secondary antibodies (GE healthcare). The blots were then visualized using
Chemiluminescent Detection Kit (Pierce).

Cell Migration and Invasion Assay
First, 24-well transwell migratory cell inserts (8 µm pores, Fisher Scientific)
were coated with 5 µg collagen 1 and incubated at 4°C overnight. Before use,
liquid was aspirated out and the inserts were rinsed with PBS and allowed to dry
in sterile condition. Cells in serum free medium were seeded into inserts in
duplicates. 500 µl of medium with 10% FBS was added to the bottom of the well
and served as an attractant. Cells were allowed to migrate through the inserts for
indicated times in the figure legend, cells that did not migrate were removed with
a cotton swab and migratory cells were fixed with 4% paraformaldehyde and
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stained with crystal violet in ethanol. Snapshots were taken of the migratory
cells, then cells were destained in 2% SDS and absorbances were read at 560
nm. For cell invasion assay, the transwell inserts were coated with matrigel
instead of collagen, and the same procedures as the migration assay were
followed.

In Vivo Migration Experiment
All procedures with mice were approved by an Institutional Animal Care
and Use Committee (IACUC) in the Division of Research Integrity and
Compliance at the University of South Florida (Protocol #R4064). The 6 week-old
female athymic nude mice weighing ~20 g were purchased from the National
Cancer Institute (NCI). A549-Luciferase and H292 human lung cancer cell lines
representing control and HDAC6 knock down cells (5×106 cells/200 µl in PBS)
were injected via tail vein into the mice. For H292 groups cells were allowed to
grow for six weeks. For A549-luciferase group, mice were injected weekly via
intraperitoneal with luciferin (from Caliper/Xenogen) in order to visualize the cells
using bioluminescence imaging. At the end of the six weeks period lungs from
mice were collected, and macroscopic analyses were perform for the presence of
nodules.

126

Statistical Analysis
Results obtained from independent studies are shown with mean ±
Standard deviation. Statistical analysis was performed using the student’s t-test.
p-value less than 0.05 was considered significant.
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FIGURES

Figure.4.1. Active Raf Promotes Cell Migration via HDAC6. c-RAF-BXB
plasmid was transfected into HDAC6 WT or KO MEFs. 40, 000 cells were
seeded into each inserts to perform the cell migration assays as described in the
Methods section. Cells were allowed to migrat for 24 hrs. Snapshots of the
migratory cells were shown as indicated. (B) The stained migratory cells were destained in 2% SDS and then quantified using a spectrophotometer at OD 560
nm. (C) Anti-P-ERK, anti-T-ERK, anti-mHDAC6, and anti-β-tubulin western blot
analyses were performed using the cell lines described in (A) and (B). NS stands
for not significant. ** indicates the p<0.001
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Figure.4.2. Seine-1035A Mutant of HDAC6 Exerts Decreased Migration
Potential in MEFs. (A) Cell migration assays were carried out using HDAC6 KO
MEFs cells stably expressing empty vector, HA-HD6-F, HA-HD6(S1035A)-F or
HA-HD6(S1035D)-F. 40, 000 cells were seeded into each inserts to perform the
cell migration assays as described in the Methods section. (A) Cells were
allowed to migrate for 24 hrs. The snapshots of the migratory cells were shown
as indicated. (B) The stained migratory cells were de-stained in 2% SDS and
then quantified at OD 560 nm. NS stands for not significant. * indicates the
p<0.01. (C) Anti-HDAC6 and anti-α-tubulin Western blot analyses were
performed using the cell lines described in (A) and (B).
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Figure.4.3. β-Catenin Knock Down Reduces Cell Migration in MEFs Cells. βcatenin was knocked down in HDAC6 WT MEFs cells before performing the
migration assay as described in the Methods section. 200, 000 cells were seeded
into each inserts, and cells were allowed to migrate for 6 hrs. The snapshots of
the migratory cells were shown as indicated (A). (B) The stained migratory cells
were de-stained in 2% SDS and then quantified at OD 560 nm. (C) Anti-total βcatenin, anti-mHDAC6 and anti-β-actin Western blot analyses were performed
using β-catenin knock down cells as used for the migration studies.
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Figure.4.4. HDAC6 Promotes Migration and Invasion in H292 Cell Lines, and
In Vivo Migration in a Mouse Model. (A), H292 cells were transfected with
control shRNA or shRNA against HDAC6 to generate stable clones. HDAC6
expression was detected by western blotting analysis using anti-HDAC6
antibody. Acetylated α-tubulin serves as control for HDAC6 deacetylase activity.
β-actin was used to ensure equal loading of protein. Cell migration and invasion
assays were carried out using H292 HDAC6 control (pRS) and HDAC6
knockdown (HD6KD) cells. 100, 000 cells were seeded into each inserts to
perform the cell migration assays as described in the Methods section. Cells
were allowed to migration or invade on collagen 1 or matrigel matrix for 24 hrs.
(B) snapshots of the migratory cells and (C) snapshots of invaded cells are
shown as indicated. Mice injected with H292 pRS or H292-HD6 were weighed
weekly for 6 weeks, and differences were plotted as shown in (D). Macroscopic
analysis of nodules on the lungs of mice injected via tail vein with H292 HD6-pRS
or H292-HD6KD cells, or lungs from normal mice that was not injected with cells
(E). Scatter plot indicates the number of nodules counted on the surface of the
lungs during macroscopic analysis (F).
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Figure.4.5. HDAC6 Promotes In Vivo Migration of Human A549 Cell in a
Mouse Model. (A), A549 cells expressing firefly Luciferase genes were
transfected with control shRNA or shRNA against HDAC6 to generate stable
clones. HDAC6 expression was detected by western blotting analysis using antiHDAC6 antibody. Acetylated α-tubulin serves as control for HDAC6 deacetylase
activity. β-actin was used to ensure equal loading of protein. B, Ex vivo imaging
of mice preformed on Day of injection (Day 0), indicating a successful injection of
luciferase expressing A549 cells. Mice injected with A549 pRS-Luc or A549HD6KD-Luc cells were weighed weekly for 6 weeks, and differences were plotted
as shown in (C). Macroscopic analysis of nodules on the lungs of mice injected
via tail vein with A549 HD6-pRS-Luc or A549-HD6KD-Luc cells, or lungs from
normal mice that was not injected with cells (D). Scatter plot indicates the
number of nodules counted on the surface of the lungs during macroscopic
analysis (E).
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Figure.4.6. HDAC6 Expression is Up-Regulated in Lung Cancer Cell Lines
Compared to the Normal Lung Cell Lines. Total protein extracts were
prepared from two normal lung cell lines (LL24 and HBE4), and several lung
cancer cell lines (ADLC, EPLC, H2172, H522, A549, H2122, H661, H460, A460,
H1299, and H292). Protein extracts were analyzed by western blotting analyses.
* indicates cell lines with a K-Ras mutation.
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CHAPTER FIVE
DISCUSSION

Overview
Acetylation and deacetylation are post translational modifications that
occur on the ε-amino group of lysine residues (1). Histone acetyltransferases
(HATs) and histone deacetylases (HDACs) catalyze this reversible reaction (1,
2). Histones were initially identified as substrates for HATs and HDACs, but it
later became apparent that numerous nonhistone proteins were also able to
undergo reversible acetylation (2, 3). In fact, several cellular processes such as
transcription, translation, DNA repair, and metabolism are regulated in part by the
actions of HATs and HDACs (2, 4).
There are 18 identified human HDACs family members group together into
four families depending on their sequence similarity and cofactor dependency
(2). Because of the different cellular processes affected by the HDACs,
divergence in their role can lead to disease states including cancer (2). In
addition, cellular processes including promotion of cellular proliferation,
metastasis, angiogenesis, apoptosis prevention and differenciation are all
hallmarks of cancer (5). Interestingly, many of the HDAC family members are
involved in promoting these processes (4, 5).
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Histone deacetylase 6 (HDAC6), is also involved in promoting cancer by
affecting cell proliferation, angiogeneisis, cell migration and metastasis (5-8).
HDAC6 promotes cells motility through its ability to deacetylate its cytoplasmic
substrates α-tubulin and cortactin, thereby affecting both the microtubule and
actin network (6, 8). HDAC6 is also required for efficient oncogenic
transformation and tumor formation (9). In addition, HDAC6 expression is upregulated in many different cancer tissues compared to their non cancerous
counterparts. HDAC6 is up-regulated in oral squamous cell carcinoma (10),
ovarian cancer tissues and cell lines (unpublished data), and in breast cancer
tissues (11). However, in contrast to the other tumor types, HDAC6 may serve
as a biomarker for endocrine responsiveness in patients with breast cancer.
Higher HDAC6 mRNA was detected in patients with smaller tumors and lower
histological grade, and in estrogen receptor α and progesterone receptor positive
tumors (11). Patients expressing higher levels of HDAC6 mRNA were found to
be more responsive to endocrine treatment compared to those with low levels
(11). Therefore, understanding the mechanisms through which HDAC6 promotes
its function, as well as understanding how different cellular pathways affect
HDAC6 roles in promoting tumorigenesis may prove beneficial.

ERK1 Phosphorylates HDAC6 to Promote Cell Migration
The extracellular signal regulated kinase (ERK)-MAPK pathway is a
phosphorylation cascade that regulates many cellular processes within the cell
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(12). Growth factors such as epidermal growth factor (EGF) activate the pathway
by binding to their respective receptor, in this case EGFR. Binding of growth
factors to receptors lead to phosphorylation and activation of Ras-RAF-MEK1/2
and ERK1/2 (12). ERK1 and ERK2 have numerous substrates both in the
cytoplasm and the nucleus. And through these substrates, ERK1/2 promote their
functions (12).
We have discovered that ERK-MAPK pathway activation leads to HDAC6
phosphorylation and HDAC6-mediated cell migration. Using mass spectrometric
analysis, we identified serine-1035 within the c-terminal region of HDAC6 as a
phosphorylation site. In addition, we also found that serine-1035 is located within
the extracellular signal regulated kinase (ERK) recognition motif (13). We
showed that ERK1 phosphorylates HDAC6 both in vitro and in vivo using
bacterial expressed HDAC6 proteins, the MEK inhibitors U0126 and PD98059,
and an unphosphorylation and phosphorylation mimicking mutants of HDAC6
serine-1035 site. For the mimicking mutants, HDAC6 amino acid serine-1035
was mutated to alanine or aspartic acid to mimic an unphosphorylation or
phosphoryation form of HDAC6, respectively. We also used active Ras and MEK,
and dominant-negative MEK to show that activation of the EGFR-Ras-Raf-MEKERK signaling axis leads to phosphorylation of HDAC6 at its serine-1035 site.
Secondly, we investigated how ERK1-mediated HDAC6 phosphorylation
affects HDAC6 deacetylase function in regards to its substrates. Using the
unphosphorylation and phosphorylation mimicking mutants of HDAC6 serine1035 site, we determined that modification at this site does not affect HDAC6’s
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ability to deacetylate core histones. It was previous shown that HDAC6
deacetylate the F-actin associated protein cortactin, to promote cell motility (8).
ERK1/2 also phosphorylates cortactin and promotes cortactin localization to sites
of dynamic actin assembly in tumor cells. Whereas, inhibiting ERK1/2
phosphorylation result in decreased lamellipodia persistence, which is necessary
for cell movement (14). We did not observe any differences in the
unphosphorylation or phosphorylation mimetics of HDAC6 to deacetylate
cortactin compared to HDAC6 wild type.
Microtubules are components of the cytoskeleton network (15). They are
highly dynamic polymers made up of α/β tubulin heterodimers (15). α-tubulin is
another HDAC6 cytoplasmic substrate involved in promoting cell motility (6, 16).
Other phosphorylation sites within HDAC6 structure affect HDAC6’s ability to
deacetylate α-tubulin differently, resulting in either enhanced or reduced function
of α-tubulin (17-19). Glycogen synthase kinase 3β (GSK-3β) phosphorylates
HDAC6 at serine-22 in its N-terminal region, enhancing deacetylation of α-tubulin
(17). Deacetylation of α-tubulin decreases its stability and results in decrease
mitochondrial motility and transport of other kinesin-1 dependent cargo (17). The
centrosomal kinase Aurora A also phosphorylates HDAC6 at an undetermined
site (19). Aurora A phosphorylation of HDAC6 stimulates HDAC6 deacetylase
activity towards α-tubulin, and leads to reduced ciliary resorption (19). Epidermal
growth factor receptor (EGFR) kinase also phosphorylates HDAC6 on its
tyrosine-570 residue (18). EGFR kinase phosphorylation of HDAC6 reduces
HDAC6 deacetylase activity towards α-tubulin, thus increasing a more stable
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form of acetylated α-tubulin and enhancing cargo transport (18). In our in vivo
studies, we found that mutation of HDAC6 at serine-1035 to either the
unphosphorylation or phosphorylation mimetics reduces HDAC6 ability to
deacetylate α-tubulin. Unphosphorylation of HDAC6 at serine-1035 inhibits
deacetylation of α-tubulin and showed reduced cell migration. In other studies
inhibiting deacetylation of α-tubulin using HDACs inhibitor was also shown to be
associated with reduced cell motility (6, 16).
β-catenin is also a cytoplasmic substrate of HDAC6 (20). EGF stimulates
HDAC6 relocalization to the cell membrane, where HDAC6 associates with and
deacetylates β-catenin leading to β-catenin stabilization (20). Stabilized β-catenin
then enters the nucleus where it activates target genes such as c-Myc (20).
Although HDAC6 is involved in β-catenin mediated cell migration through a
complex with cell surface marker CD133, the exact mechanism remains unclear
(21). After we found that EGF leads to activation of the ERK-MAPK pathway, and
HDAC6 phosphorylation, we questioned whether ERK-mediated phosphorylation
of HDAC6 enhances deacetylation of β-catenin. Using HDAC6 unphosphorylated
and phosphorylated mimetics, we determined that the phosphorylation mimicking
mutant of HDAC6 enhanced deacetylation of β-catenin similar to that of HDAC6
wild type. We further performed transwell migration studies by first knocking
down β-catenin using siRNA techniques in HDAC6 expressing MEFs. We
observed reduced migration of cells in the β-catenin knock down group
compared to the control siRNA group. Therefore, it is possible that HDAC6
promotes cell migration through deacetylation of β-catenin.
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HDAC6 Promotes In Vivo Cell Migration
Cell migration and tumor metastasis are processes of epithelial
mesenchymal transition (22). Tumor cells acquire motile characteristics through
activation or repression of transcription factors. Tumor cells are then able to gain
access to the blood stream or lymph nodes and travel to other sites within the
body (22). Cells that survive, extravasate into surrounding tissues where they
initiate new tumor growth (22). HDAC6 is required for efficient oncogenic
transformation and tumor formation (9). Our group has also shown that depleting
HDAC6 in human lung cancer cell line H292 decreases tumor weight and tumor
volume in a xenograft model (23). HDAC6 is well known to promote cell migration
in cell line models (6, 8), but whether this is true in vivo has not been shown. Cell
migration in vitro is thought to be a reflection of cellular function in tumor
formation and metastasis in vivo. In this study, we used the tail vein injection
method to show for the first time that HDAC6 promotes migration of human lung
cancer cell in vivo. We used macroscopic analysis to determine the number of
nodules on the surface of the lung of athymic nude mice following a six weeks
period. In the HDAC6 expressing cells we observed a significant increase
(p<0.045) in the number of nodules compared to the HDAC6 deficient
counterparts in A549 human lung cancer cell lines. We also observed a non
significant increase in the number of nodules in the presence of HDAC6 when
H292 human lung cancer cells were used. However, we believe that the non
significant increase seen in the H292 group was due to the small sample size
used in this study. In both cases, we did not observe any nodules on the
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surrounding tissues and organs. Further analysis on the collected lung sample
will be used to determine protein expression in the HDAC6 expressing verses the
HDAC6 deficient groups. Interestingly, in another study, A549 cells injected
directly into the liver of mice resulted in wide spread metastasis to the lung,
spleens and lymph node by week 6 and 7 (24). In addition, the group that
performed this study used twice as many cells in their experiment, which may
account for the widespread metastasis (24). Overall, we have provided results in
support of HDAC6 mediated migration in vivo.

Considering HDAC Inhibitors as Novel Therapeutic Agents
Histone deacetylase inhibitors (HDACi) have been the focus of many
research efforts, either alone or in combination with other drug treatments (25).
Overall, HDACi in combination with other drugs have shown some promising
results (25). Depletion of HDAC6 in non-small cell lung cancer cell lines
sensitizes cells to cisplatin treatment (23). HDACi or down-regulation of HDAC1
and HDAC6 using shRNA techniques enhances cytarabine-induced apoptosis in
pediatric acute myeloid leukemia cells (26). Tubacin is an HDAC6 specific
inhibitor (16). The used of tubacin showed higher antiproliferative effect and
apoptosis induction in acute lymphoblastic leukemia (ALL). In addition, tubacin
enhances the effect of chemotherapy for treatment of primary ALL both in vitro
and in vivo (27). Finally, inhibiting HDAC6 using tubacin, enhances cell death
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induced by the topoisomerase II inhibitors etoposide and doxorubicin, and the
HDACi vorinostat (28).
Other associated proteins uncovered in this study also serves as a
suitable therapeutic targets as well. The ERK-MAPK pathway promotes
tumorigenesis via upstream activating mutations within the pathway (29, 30). The
ERK-MAPK pathway activation promotes cell migration, metastasis, apoptosis
and angiogenesis (29, 30). ERK 1/2 also phosphorylates several proteins that
promote cell migration. These proteins include myosin light chain kinase, calpain,
focal adhesion kinase and paxillin (31). These proteins also regulate the
dynamics of focal adhesion, reorganization of microtubules and filamentous
actin, cell spreading and lamellipodium extension involve in cell movement (31).
ERK 1/2 are also up-regulated in HDAC6 deficient lung cancer cell lines, and
these cell types were also shown to be more sensitive to MEK inhibitors
compared to cells expressing HDAC6 (32). HDAC6 cytoplasmic substrate βcatenin, is up-regulated in many cancer types including cancer of the colon, lung
and breast (33). Interestingly, the convergence of the canonical Wnt pathway
through β-catenin, and the ERK-MAPK pathway through EGF and EGFR
activation is already documented (20, 34). Therefore, HDAC6 specific inhibitor in
combination with an ERK1/2 inhibitor appears to be an effective therapeutic
agent.
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Significance of this Study
HDAC6 promotes cell motility through deacetylation of its cytoplasmic
substrates α-tubulin, and cortactin, thereby affecting the microtubule and the
actin network (6, 8). HDAC6 expression is up-regulated in many different cancer
tissues compared to their normal tissue counterpart (10, 11), and animal models
implicate HDAC6 in tumorigenesis (9). Understanding the mechanisms through
which HDAC6 promotes cell motility and metastasis will be beneficial for
designing HDAC6 specific inhibitors. We have identified serine-1035 as a novel
phosphorylation site of HDAC6, and ERK1 as the kinase targeting this site. We
showed that phosphorylation of HDAC6 at the serine-1035 site facilitates
HDAC6-mediated cell migration through its cytoplasmic substrates α-tubulin and
β-catenin. Because ERK1/2 also promotes tumorigenesis through activating
mutations (29), inhibitors of the ERK-MAPK pathway are also the focus of many
research efforts. It is plausible that both HDAC6 specific inhibitors and ERK1/2
inhibitors combination can be beneficial for cancer treatments.

Limitations and Future Studies
To prove that ERK1 phosphorylates HDAC6, we used a series of MEK
inhibitors, active and dominant-negative kinases, and unphosphorylation and
phosphorylation mimetics of HDAC6. However, during the preparation of this
dissertation we were able to obtain preliminary data on the phospho site specific
antibody of HDAC6 (p-S1035). In the presence of EGF treatment, HDAC6
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phosphorylation level was increased compared to the non-EGF treatment group.
HDAC6 phosphorylation in the presence of EGF was concurrent with an increase
in ERK1/2 phosphorylation downstream. Overall, generation of the site specific
antibody and further optimization will give us the ability to detect whether ERKmediated phosphorylation of HDAC6 is also up-regulated in cancer patient’s
tissue samples. In the in vivo migration model, we used tail vein injection. This
procedure allows, a rapid time course. In this model, early stages in the
metastatic cascade such as cell invasion into surrounding tissues, and
intravasation into the blood stream were eliminated. In the tail vein models, cells
usually circulate in high number, and it is unlikely that they will interact with the
target tissue in the same way as spontaneous metastasizing cells. As such,
different metastasizing cells may have a different genetic profile (35).
HDAC6 was shown to affect other cellular processes involved in the EMT
process including angiogenesis and cellular adhesion (7, 36). It will be interesting
to determine how ERK1-mediated HDAC6 phosphorylation affects these
processes as well. Future projects are aimed at deciphering the role of HDAC6 in
these processes. Obtaining the site specific antibody may also prove to be
beneficial. Previously, we used the unphosphorylation and phosphorylation
mimicking mutants and mass spectrometric analysis to identify any additional
interacting protein of HDAC6, however, this technique was unsuccessful. With
the use of the site specific antibody we hope to determine whether
phosphorylated HDAC6 localization differs from HDAC6 wild type and whether
there are additional proteins that interact with HDAC6 to promote cell migration.
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